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A B S T R A C T
Background
Early, accurate detection of all skin cancer types is essential to guide appropriate management and to improve morbidity and survival.
Melanoma and squamous cell carcinoma (SCC) are high-risk skin cancers with the potential to metastasise and ultimately lead to death,
whereas basal cell carcinoma (BCC) is usually localised, with potential to infiltrate and damage surrounding tissue. Anxiety around
missing early curable cases needs to be balanced against inappropriate referral and unnecessary excision of benign lesions. Ultrasound
is a non-invasive imaging technique that relies on the measurement of sound wave reflections from the tissues of the body. At lower
frequencies, the deeper structures of the body such as the internal organs can be visualised, while high-frequency ultrasound (HFUS)
with transducer frequencies of 20 MHz or more has a much lower depth of tissue penetration but produces a higher resolution image
of tissues and structures closer to the skin surface. Used in conjunction with clinical and/or dermoscopic examination of suspected skin
cancer, HFUS may offer additional diagnostic information compared to other technologies.
Objectives
To assess the diagnostic accuracy of HFUS to assist in the diagnosis of a) cutaneous invasive melanoma and atypical intraepidermal
melanocytic variants, b) cutaneous squamous cell carcinoma (cSCC), and c) basal cell carcinoma (BCC) in adults.
Search methods
We undertook a comprehensive search of the following databases from inception up to August 2016: Cochrane Central Register of
Controlled Trials; MEDLINE; Embase; CINAHL; CPCI; Zetoc; Science Citation Index; US National Institutes of Health Ongoing
Trials Register; NIHR Clinical Research Network Portfolio Database; and the World Health Organization International Clinical Trials
Registry Platform. We studied reference lists as well as published systematic review articles.
Selection criteria
Studies evaluating HFUS (20 MHz or more) in adults with lesions suspicious for melanoma, cSCC or BCC versus a reference standard
of histological confirmation or clinical follow-up.
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Data collection and analysis
Two review authors independently extracted all data using a standardised data extraction and quality assessment form (based on
QUADAS-2). Due to scarcity of data and the poor quality of studies, we did not undertake ameta-analysis for this review. For illustrative
purposes, we plot estimates of sensitivity and specificity on coupled forest plots.
Main results
We included six studies, providing 29 datasets: 20 for diagnosis of melanoma (1125 lesions and 242 melanomas) and 9 for diagnosis
of BCC (993 lesions and 119 BCCs). We did not identify any data relating to the diagnosis of cSCC.
Studies were generally poorly reported, limiting judgements of methodological quality. Half the studies did not set out to establish
test accuracy, and all should be considered preliminary evaluations of the potential usefulness of HFUS. There were particularly high
concerns for applicability of findings due to selective study populations and data-driven thresholds for test positivity. Studies reporting
qualitative assessments of HFUS images excluded up to 22% of lesions (including some melanomas) due to lack of visualisation in the
test.
Derived sensitivities for qualitative HFUS characteristics were at least 83% (95% CI 75% to 90%) for the detection of melanoma; the
combination of three features (lesions appearing hypoechoic, homogenous and well defined) demonstrating 100% sensitivity in two
studies (lower limits of the 95% CIs were 94% and 82%), with variable corresponding specificities of 33% (95% CI 20% to 48%) and
73% (95% CI 57% to 85%), respectively. Quantitative measurement of HFUS outputs in two studies enabled decision thresholds to
be set to achieve 100% sensitivity; specificities were 93% (95% CI 77% to 99%) and 65% (95% CI 51% to 76%). It was not possible
to make summary statements regarding HFUS accuracy for the diagnosis of BCC due to highly variable sensitivities and specificities.
Authors’ conclusions
Insufficient data are available on the potential value of HFUS in the diagnosis of melanoma or BCC. Given the between-study
heterogeneity, unclear to low methodological quality and limited volume of evidence, we cannot draw any implications for practice.
The main value of the preliminary studies included may be in providing guidance on the possible components of new diagnostic rules
for diagnosis of melanoma or BCC using HFUS that will require future evaluation. A prospective evaluation of HFUS added to visual
inspection and dermoscopy alone in a standard healthcare setting, with a clearly defined and representative population of participants,
would be required for a full and proper evaluation of accuracy.
P L A I N L A N G U A G E S U M M A R Y
How accurate is high-frequency ultrasound for diagnosing skin cancer in adults?
Why is improving the diagnosis of skin cancer important?
There are several types of skin cancer. Melanoma is one of the most dangerous forms, so it is important to detect it early and remove
it as soon as possible. Failure to recognise melanoma for what it is (known as a false negative test result) can delay treatment, risking
the spread of melanoma to other organs in the body and possibly premature death. Other skin cancers, like cutaneous squamous cell
carcinoma and basal cell carcinoma, are more localised. However, cutaneous squamous cell carcinoma can spread to other parts of the
body, and basal cell carcinoma can cause disfigurement if left untreated. Diagnosing a harmless lesion (a mole or area of skin with an
unusual appearance in comparison with the surrounding skin) as skin cancer (a false positive result) may result in unnecessary surgery
and other tests that can cause stress and anxiety to the patient. Mistaking one skin cancer for another can lead to the wrong treatment
or delays in effective treatment. Thus, the correct diagnosis is important.
What is the aim of the review?
We wanted to find out whether high-frequency ultrasound can help doctors diagnose skin cancer. We found six studies to try and
answer this question. Five studies investigated the diagnosis of melanoma and three, basal cell carcinoma.
What was studied in the review?
A number of tools allow skin cancer specialists to examine the skin in more detail than by the naked eye alone. Most skin cancer
specialists currently use a dermatoscope, which magnifies the skin lesion using a natural light. Ultrasound is another non-invasive
technique that measures sound wave reflections from body tissues. High-frequency ultrasound can produce a good-quality image of
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structures closer to the skin surface.When used alongside a doctor’s examination and dermoscopy, high-frequency ultrasound may help
doctors make a more accurate diagnosis.
What are the main results of the review?
The review included six studies: five with 1125 skin lesions suspected of being melanoma, and three with 993 lesions suspected of
being basal cell carcinoma. We did not find any studies on the diagnosis of cutaneous squamous cell carcinoma.
The included studies were small and too different from each other to allow reliable estimates of accuracy to be made for identifying
melanoma or basal cell carcinoma. Half were not actually designed to establish test accuracy and all can be considered preliminary
experiments on the potential value of high-frequency ultrasound. The main value of the studies may be in helping researchers to identify
the best ways of interpreting high-frequency ultrasound for the diagnosis of melanoma or basal cell carcinoma for evaluation in future
research studies.
How reliable are the results?
Study results are not very reliable when considered collectively. The small number and variability between studies reduces reliability,
while all had important limitations. In particular, those taking part in the studies and the way in which the tests were used may not
reflect real life situations. In all studies the final diagnosis was confirmed by biopsy. This is likely to have been a reliable method for
deciding whether patients really had skin cancer*.
Who do the results of this review apply to?
Studies all took place in Europe, and only one reported participants’ average age (55.3 years). The percentage of people with a final
diagnosis of melanoma ranged from 14% to 58%, while 8% to 49% had basal cell carcinoma. It was not possible to tell whether doctors
suspected skin cancer based on clinical examination alone or both clinical and dermoscopic examination.
What are the implications of this review?
At present, there is not enough good research to draw a conclusion on using high-frequency ultrasound for diagnosing skin cancers.
The results of this review suggest that high-frequency ultrasound has potential to separate melanoma or basal cell carcinoma from
some harmless types of lesions, but it is still unclear whether it can adequately distinguish these skin cancers from the full range of
skin conditions that patients show their doctors in everyday practice. There is a need for more studies investigating high-frequency
ultrasound alongside dermoscopy or other microscopic techniques (such as reflectance confocal microscopy) in people with suspicious
skin lesions.
How up-to-date is this review?
The review authors searched for and used studies published up to August 2016.
*In these studies biopsy was the reference standard (means of establishing the final diagnosis).
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Question What is the diagnost ic accuracy of high-f requency ultrasound (HFUS) for diagnosing cutaneous melanoma or BCC in adults?
Participants Adults with suspicious skin lesions
Prior testing and preva-
lence
Studies varied in, or did not report , the basis for part icipant referral for ultrasound. One implied that half of included lesions were dif f icult to
diagnose, and two included only 3 lesion types. Prevalence of melanoma ranged f rom 14% to 58% (median 30%) and BCC f rom 8% to 49% (median
17%)
Settings Secondary care and specialist lesion clinics
Target condition(s) Invasive melanoma and atypical intraepidermal melanocyt ic variants; basal cell carcinoma
Index test High-f requency ultrasound (> 20 MHz) alone or in combinat ion with Doppler ultrasound. Lesions not visualised on ultrasound were excluded by
some studies
Reference standard Histology
Action: If accurate, posit ive results of HFUS will help to appropriately select lesions for excision
Limitations
Risk of bias: Pat ient select ion methods unclear or at high risk of bias due to select ive inclusion of lesion types. Test interpretat ion was blinded to reference
standard, but test thresholds were clearly prespecif ied in only 1 study and were data driven (2/ 6) or not pre-specif ied (3/ 6) in the remainder.
Reference standard blinding was not described. Tim ing of index and reference standards was not reported. Exclusions due to test failures were
not reported (3/ 6)
Applicability of evidence to
quest ion:
High (4 studies) or unclear (1 study) concerns about applicability due to unrepresentat ive part icipant samples with high disease prevalence. Test
observers were not described (6/ 6 studies) and prototype or relat ively novel devices used (2/ 6 studies). Reference standard interpretat ion by
experienced histopathologists was not described (5/ 6 studies). Half the studies were not designed to invest igate test accuracy
Total number of studies 6 Total part icipants with test
results
1263 Total number melanoma or BCC 349
Detection of melanoma
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Number of studies 5 Total part icipants with test
results
1125 Total with melanoma 242
Findings No pooled analysis conducted due to between-study heterogeneity and small study numbers. Derived sensit ivit ies for invest igated HFUS
characterist ics were at least 83% (95%CI 75% to 90%); the combinat ion of 3 qualitat ive features (lesions appearing hypoechoic, homogenous and
well def ined) demonstrat ing 100% sensit ivity in 2 studies, with variable specif icit ies of 33% (95% CI 20% to 48%) and 73% (95% CI 57% to 85%).
Quantitat ive measurement of HFUS outputs in 2 studies enabled decision thresholds to be set to achieve 100% sensit ivity; result ing specif icit ies
were 93% (95% CI 77% to 99%) and 65% (95% CI 51% to 76%). Between 7 and 38 lesions were not visualised on HFUS (reported in 3 studies);
including between 3 and 5 melanomas not visualised (in each of the 3 studies)
Detection of BCC
Number of studies 3 Total part icipants with test
results
993 Total with BCC 119
Findings Only qualitat ive thresholds were assessed; sensit ivit ies and specif icit ies were highly variable, making summary statements dif f icult
HFUS: high-f requency ultrasound; BCC: basal cell carcinoma; CI: conf idence interval.
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B A C K G R O U N D
This review is one in a suite of Cochrane Diagnostic Test Accu-
racy (DTA) Reviews on the diagnosis and staging of melanoma
and keratinocyte skin cancers, conducted for the National Insti-
tute for Health Research (NIHR) Cochrane Systematic Reviews
Programme. Appendix 1 shows the content and structure of the
programme. Appendix 2 provides a glossary of terms used, and
Appendix 3 a table of acronyms used.
Target condition being diagnosed
There are threemain forms of skin cancer.Melanoma has the high-
est skin cancer mortality (Cancer Research UK 2017); however,
the most common skin cancers in white populations arise from
keratinocyte cells: basal cell carcinoma and cutaneous squamous
cell carcinoma (Gordon 2013; Madan 2010). In 2003, the World
Health Organization (WHO) estimated that 2 to 3 million non-
melanoma skin cancers (of which BCC and cSCC are estimated
to account for around 80% and 16% of cases, respectively) and
132,000 melanoma skin cancers occur globally each year (WHO
2003).
This DTA review has three target conditions of interest:
melanoma, basal cell carcinoma (BCC), and cutaneous squamous
cell carcinoma (cSCC).
Melanoma
Melanoma arises from uncontrolled proliferation of melanocytes
- the epidermal cells that produce pigment or melanin. Cutaneous
melanoma refers to any skin lesion with malignant melanocytes
present in the dermis and includes superficial spreading, nodu-
lar, acral lentiginous and lentigo maligna melanoma variants (see
Figure 1). Melanoma in situ refers to malignant melanocytes that
are contained within the epidermis and have not yet invaded the
dermis but are at risk of progression to melanoma if left untreated.
Lentigo maligna, a subtype of melanoma in situ in chronically
sun-damaged skin, denotes another form of proliferation of ab-
normal melanocytes. Melanoma in situ and lentigo maligna are
both atypical intraepidermal melanocytic variants. All forms of
melanoma in situ can progress to invasive melanoma if growth
breaches the dermo-epidermal junction during a vertical growth
phase, althoughmalignant transformation is both lower and slower
for lentigo maligna than for melanoma in situ (Kasprzak 2015).
Melanoma is one of the most dangerous forms of skin cancer,
with the potential to metastasise to other parts of the body via the
lymphatic system and blood stream. It accounts for only a small
percentage of skin cancer cases but is responsible for up to 75%
of skin cancer deaths (Boring 1994; Cancer Research UK 2017).
Figure 1. Sample photographs of superficial spreading melanoma (left), BCC (centre), and cSCC (right).
Copyright © 2012 Dr Rubeta Matin: reproduced with permission.
The incidence of melanoma rose to over 200,000 newly diagnosed
cases worldwide in 2012 (Erdmann 2013; Ferlay 2015), with an
estimated 55,000 deaths (Ferlay 2015). The highest incidence is
observed in Australia, with 13,134 new cases of melanoma of the
skin in 2014 (ACIM 2017), and in New Zealand with 2341 regis-
tered cases in 2010 (HPA andMelNet NZ 2014). In the USA, the
predicted incidence in 2014 was 73,870, and the predicted num-
ber of deaths 9940 (Siegel 2015). The highest rates in Europe are
in north-western Europe and Scandinavia, with the highest inci-
dence reported in Switzerland at 25.8 per 100,000 in 2012. Rates
in England have tripled from 4.6 and 6.0 per 100,000 in men
and women, respectively, in 1990, to 18.6 and 19.6 per 100,000
in 2012 (EUCAN 2012). Indeed, in the UK, melanoma has one
of the fastest rising incidence rates of any cancer, with the biggest
projected increase in incidence between 2007 and 2030 (Mistry
6High-frequency ultrasound for diagnosing skin cancer in adults (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
2011). In the decade leading up to 2013, age-standardised inci-
dence increased by 46%, with 14,500 new cases in 2013 and 2459
deaths in 2014 (Cancer Research UK 2017). Rates are higher in
women than in men; however, the rate of incidence in men is
increasing faster than in women (Arnold 2014). The rising inci-
dence in melanoma is thought to be primarily related to an in-
crease in recreational sun exposure and tanning bed use and an
increasingly ageing population with higher lifetime recreational
ultraviolet (UV) exposure, in conjunction with possible earlier de-
tection (Belbasis 2016; Linos 2009). Belbasis 2016 provides a de-
tailed review of putative risk factors, including eye and hair colour,
skin type and density of freckles, history of melanoma, sunburn,
and presence of particular lesion types.
A database in the USA of over 40,000 patients from 1998 on-
wards, which assisted in the development of the 8th American
Joint Committee on Cancer (AJCC) Staging System, indicated a
five-year survival of 97% to 99% for stage I melanoma, which
dropped to 32% to 93% in stage III disease depending on tu-
mour thickness, the presence of ulceration and number of involved
nodes (Gershenwald 2017). While these are substantial increases
relative to survival in 1975 (Cho 2014), increasing incidence be-
tween 1975 and 2010 means that reported mortality rates have re-
mained static. This observation, coupledwith increasing incidence
of localised disease, suggests that improvements in survival may
be due to earlier detection and heightened vigilance (Cho 2014).
New targeted therapies for advanced (stage IV), melanoma (e.g.
BRAF inhibitors), have improved survival, and immunotherapies
are evolving such that long-term survival is being documented
(Pasquali 2018; Rozeman 2017). No new data regarding the sur-
vival prospects for patients with stage IV disease were analysed for
the AJCC 8 staging guidelines due to lack of contemporary data
(Gershenwald 2017).
Basal cell carcinoma
BCCcan arise frommultiple stem cell populations, including from
the follicular bulge and interfollicular epidermis (Grachtchouk
2011). BCC growth is usually localised, but it can infiltrate and
damage surrounding tissue, sometimes causing considerable de-
struction and disfigurement, particularly when located on the face
(Figure 1). The fourmain subtypes of BCCare superficial, nodular,
morphoeic or infiltrative, and pigmented. BCCs typically present
as slow-growing, asymptomatic papules, plaques or nodules that
may subsequently bleed or form ulcers that do not heal (Firnhaber
2012). People with a BCC often present to healthcare profession-
als with a non-healing lesion rather than specific symptoms such
as pain. Many lesions are diagnosed incidentally (Gordon 2013).
BCC most commonly occurs on sun-exposed sites on the head
and neck (McCormack 1997), and they are more common inmen
and in people over the age of 40. Different authors have attributed
a rising incidence of BCC in younger people to increased recre-
ational sun exposure (Bath-Hextall 2007; Gordon 2013; Musah
2013). Other risk factors include Fitzpatrick skin phototypes I
and II (Fitzpatrick 1975; Lear 1997; Maia 1995), a history of skin
cancer, immunosuppression, arsenic exposure, and genetic predis-
position such as in basal cell naevus (Gorlin) syndrome (Gorlin
2004; Zak-Prelich 2004). Annual incidence is rising worldwide;
Europe has experienced an average increase of 5.5% per year over
the last four decades, and the USA of 2% per year, while esti-
mates for the UK show that incidence appears to be increasing
more steeply at a rate of an additional 6 per 100,000 persons per
year (Lomas 2012). The rising incidence has been explained by
an ageing population, changes in the distribution of known risk
factors, particularly ultraviolet radiation, and improved detection
due to the increased awareness amongst both practitioners and the
general population (Verkouteren 2017). Hoorens 2016 points to
evidence for a gradual increase in the size of BCCs over time, with
delays in diagnosis ranging from 19 to 25 months.
According to National Institute for Health and Care Excellence
(NICE) guidance (NICE 2010), low-risk BCCs are nodular le-
sions occurring in patients older than 24 years old who are not im-
munosuppressed and do not have Gorlin syndrome. Furthermore,
they should be located below the clavicle, should be small (diame-
ter of less than 1 cm) with well-definedmargins, not recurrent fol-
lowing incomplete excision and not in awkward or highly visible
locations (NICE 2010). Superficial BCCs are also typically low
risk and may be amenable to medical treatments such as photody-
namic therapy or topical chemotherapy (Kelleners-Smeets 2017).
Assigning BCCs a low or high risk influences the management
options (Batra 2002; Randle 1996).
Advanced locally destructive or aggressive BCC can be found on
’high-risk’ anatomical areas such as the eyebrow, eyelid, nose, ear
and temple (these are at higher risk of invisible spread and therefore
are more at risk of being incompletely excised (Baxter 2012; Lear
2014)), and they can arise from long-standing untreated lesions or
from a recurrence of aggressive basal cell carcinoma after primary
treatment (Lear 2012). Very rarely, BCC metastasises to regional
and distant sites, resulting in death, especially cases of large ne-
glected lesions in those who are immunosuppressed or those with
Gorlin syndrome (McCusker 2014). Rates of metastasis are re-
ported at 0.0028% to 0.55% (Lo 1991), with very poor survival
rates. It is recognised that basosquamous carcinoma (more like a
high-risk SCC in behaviour and not considered a true BCC) is
likely to have accounted for many cases of apparent metastases of
BCC, hence the spuriously high reported incidence in some stud-
ies of up to 0.55%, which is not seen in clinical practice (Garcia
2009).
Squamous cell carcinoma of the skin
Primary cSCC arises from the keratinising cells of the epidermis
or its appendages. People with cSCC often present with an ulcer
or firm (indurated) papule, plaque or nodule (Griffin 2016), often
with an adherent crust and poorly definedmargins (Madan 2010).
This type of carcinoma can arise in the absence of a precursor
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lesion or can develop from pre-existing actinic keratosis or Bowen’s
disease (considered by some to be cSCC in situ); the estimated
annual risk of progression being less than 1% to 20% for newly
arising lesions (Alam 2001), and 5% for pre-existing lesions (Kao
1986). It remains locally invasive for a variable length of time, but
it has the potential to spread to the regional lymph nodes or via
the bloodstream to distant sites, especially in immunosuppressed
individuals (Lansbury 2010).High-risk lesions are those arising on
the lip or ear, recurrent cSCC, lesions arising on non-exposed sites,
scars or chronic ulcers, tumours more than 20 mm in diameter,
depth of invasion greater than 4 mm and poor differentiation on
pathological examination (Motley 2009). Perineural invasion of
nerves at least 0.1 mm in diameter is a further documented risk
factor for high-risk cSCC (Carter 2013).
Chronic ultraviolet light exposure through recreation or occupa-
tion is strongly linked to cSCC occurrence (Alam 2001). It is
particularly common in people with fair skin and in less com-
mon genetic disorders of pigmentation, such as albinism, xero-
derma pigmentosum, and recessive dystrophic epidermolysis bul-
losa (RDEB) (Alam 2001). Other recognised risk factors include
immunosuppression; chronic wounds; arsenic or radiation expo-
sure; certain drug treatments, such as voriconazole and BRAFmu-
tation inhibitors; and previous skin cancer history (Baldursson
1993; Chowdri 1996; Dabski 1986; Fasching 1989; Lister 1997;
Maloney 1996; O’Gorman 2014). In solid organ transplant re-
cipients, cSCC is the most common form of skin cancer; the risk
of developing cSCC has been estimated at 65 to 253 times that of
the general population (Hartevelt 1990; Jensen 1999; Lansbury
2010). Overall, local and metastatic recurrence of cSCC at five
years is estimated at 8% and 5%, respectively. The five-year sur-
vival rate of metastatic cSCC of the head and neck is around 60%
(Moeckelmann 2018).
Treatment
For primary melanoma, the mainstay of definitive treatment is
wide local surgical excision of the lesion, to remove both the tu-
mour and any malignant cells that might have spread into the sur-
rounding skin (Garbe 2016; Marsden 2010; NICE 2015a; SIGN
2017; Sladden 2009). Recommended lateral surgical margins vary
according to tumour thickness, as described in Garbe 2016, and to
stage of disease at presentation, as recommended in NICE 2015a.
Treatment options for BCC and cSCC include surgery, other
destructive techniques such as cryotherapy or electrodessication,
and topical chemotherapy. A Cochrane Review of 27 randomised
controlled trials (RCTs) of interventions for BCC found very
little good-quality evidence for any of the interventions used
(Bath-Hextall 2007a). Complete surgical excision of primary BCC
has a reported five-year recurrence rate of less than 2% (Griffiths
2005; Walker 2006), leading to significantly fewer recurrences
than treatment with radiotherapy (Bath-Hextall 2007a).With ap-
parently clear histopathological margins (serial vertical sections)
following standard excision biopsy with 4 mm surgical periph-
eral margins, there is a reported recurrence rate of around 4% at
five years (Drucker 2017). Mohs micrographic surgery, whereby
surgeons microscopically examine horizontal sections of the tu-
mour intraoperatively, undertaking re-excision until the margins
are tumour-free, are options for high-risk lesions on the face where
standard wider excision margins might lead to incomplete exci-
sion or considerable functional impairment (Bath-Hextall 2007a;
Lansbury 2010; Motley 2009; Stratigos 2015). Bath-Hextall
2007a found a single trial comparing Mohs micrographic surgery
with a 3 mm surgical margin excision in BCC (Smeets 2004); the
update of this study showed non-significantly lower recurrence
at 10 years with Mohs micrographic surgery (4.4% compared to
12.2% after surgical excision, P = 0.10) (van Loo 2014).
The main treatments for high-risk BCC are standard surgical exci-
sion, Mohs micrographic surgery or radiotherapy. For low-risk or
superficial subtypes of BCC, or for small and or multiple BCCs at
low-risk sites (Marsden 2010), destructive techniques other than
excisional surgery may be used (e.g. electrodessication and curet-
tage or cryotherapy (Alam 2001; Bath-Hextall 2007a)). Alterna-
tively, non-surgical (or non-destructive) treatments may be con-
sidered (Bath-Hextall 2007a; Drew 2017; Kim 2014), including
topical chemotherapy imiquimod (Williams 2017), 5-fluorouracil
(5-FU) (Arits 2013), ingenol mebutate (Nart 2015), and photo-
dynamic therapy (PDT) (Roozeboom 2016). Non-surgical treat-
ments are most frequently used for superficial forms of BCC, with
one head-to-head trial suggesting topical imiquimod is superior
to PDT and 5-FU (Jansen 2018). Although use of non-surgical
techniques is increasing, these do not allow histological confir-
mation of tumour clearance, and their use depends on accurate
characterisation of the histological subtype and depth of tumour.
The 2007 Cochrane Review of BCC interventions found limited
evidence from very small RCTs for these approaches (Bath-Hextall
2007a), which have only partially been addressed by subsequent
studies (Bath-Hextall 2014; Kim 2014; Roozeboom 2012). Most
BCC trials have compared interventions within the same treat-
ment class, and few have compared medical versus surgical treat-
ments (Kim 2014).
Vismodegib, a first-in-class Hedgehog signalling pathway in-
hibitor, is now available for treating metastatic or locally advanced
BCCbased on the pivotal study ERIVANCEBCC (Sekulic 2012).
It is licensed for use in patients where surgery or radiotherapy is
inappropriate, e.g. for treating locally advanced periocular and or-
bital BCCs with orbital salvage of patients who otherwise would
have required exenteration (Wong 2017). However, NICE has re-
cently advised against the use of vismodegib based on cost-effec-
tiveness and uncertainty of evidence (NICE 2017).
A systematic review of interventions for primary cSCC found only
one RCT eligible for inclusion (Lansbury 2010). Current practice
therefore relies on evidence fromobservational studies, as reviewed
in Lansbury 2013, for example. Surgical excision with predeter-
mined margins is usually the first-line treatment (Motley 2009;
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Stratigos 2015). Estimates of recurrence after Mohs micrographic
surgery, surgical excision, or radiotherapy, which are likely to have
been evaluated in higher-risk populations, have shown pooled re-
currence rates of 3%, 5.4% and 6.4%, respectively, with overlap-
ping confidence intervals; the review authors advise caution when
comparing results across treatments (Lansbury 2013).
Index test(s)
Ultrasound is a non-invasive imaging technique that essentially
relies on the measurement of sound wave reflections from the tis-
sues of the body. A transducer generates a focused beam of sound
pulses, measuring the reflections (or echoes) produced by struc-
tures within the tissue. The spatial location of a tissue structure
that produced an echo is determined in the lateral direction (paral-
lel to the skin surface) by the position of the sound beam (known)
and in the axial (depth) direction by the return time of the echo
(measured) and the speed of sound in the tissue (known to a good
approximation) (Figure 2; Barcaui 2016; Kleinerman 2012). An
important parameter is the range of acoustic frequencies used to
form the image. While low-frequency ultrasound visualises the
deeper structures of the body, such as the internal organs, high-
frequency ultrasound (HFUS), defined here as having centre (or
median) frequency of at least 20 MHz, has a much lower depth of
tissue penetration but produces a higher resolution image of tis-
sues and structures closer to the skin surface (Kleinerman 2012).
Frequencies of 20 MHz to 25 MHz allow visualisation of both
the dermis and epidermis while higher frequencies of 50 MHz
and above visualise the epidermis only (Kleinerman 2012). Figure
3 shows an example of a currently commercially available HFUS
scanner; the cost of the system can range from EUR 5500 for
a Windows tablet-based non-real-time system that works at 20
MHz (not shown) to around EUR 27,000 for a laptop-based sys-
tem (Figure 3) which provides real-time images and works up to
a frequency of 50 MHz (as well as 20 MHz) (Svendson 2018).
Figure 2. The principles of B-mode ultrasound echographic imaging of the skin.
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Figure 3. Modern laptop based DermaScan C (2D). Copyright © 2018 Cortex Technology ApS: reproduced
with permission.
In B-mode (brightness mode) ultrasound echography, the image
brightness is modulated according to the amplitude of the echoes
(echogenicity). This in turn is determined by the values of sound
speed and mass-density within an echo-producing structure rel-
ative to those values in the surrounding medium, and the size,
shape, orientation, andnumber-density of such structures (Barcaui
2016). Please see the following examples.
• Structural proteins, such as collagen and keratin, are dense
and have high sound speed, and they generate strong echoes
(termed hyperechoic or echogenic) when the fibres are thick,
densely packed, and oriented mostly perpendicular to the
ultrasound beam (e.g. reticular dermis).
• Adipose tissue, highly cellular lesions with little collagen or
keratin, and regions where the collagen bundle size is small
(some lesions) and/or oriented mostly parallel to the sound beam
(e.g. papillary dermis) generate weak echoes (termed hypoechoic
or echo poor).
• Liquids (e.g. as in simple cysts) generate no echoes and are
referred to as anechoic (Bamber 1992; Harland 1993).
Researchers have investigated the use of HFUS for diagnosing a
range of skin conditions, including skin cancer, infection, and
inflammatory conditions (Kleinerman 2012), with malignant le-
sions reportedly appearing as hypoechogenic areas surrounded by
a hyperechogenic dermis. Melanomas in particular also reportedly
appear homogenous and with well-defined margins (e.g. Harland
2000). Evaluations have also been made of the ability of HFUS to
quantitatively differentiate melanomas from other lesion types us-
ing entry echogenicity and attenuation (the latter being the rate of
reduction in echo signal with depth). These features have been re-
ported to be particularly useful for distinguishing melanoma from
seborrhoeic keratosis, for example (Harland 2000; Rallan 2007;
see Figure 4), and they are measurable even when a given lesion
cannot be visualised on ultrasound.
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Figure 4. Illustrates the well defined margins, low level and homogenous internal echoes, lack of strong
entry echo and lack of acoustic shadowing for melanoma (c. and d.) and contrasting image for BCC (a. and b.)
(from Harland 2000, Copyright © 2000 John Wiley and Sons, reproduced with permission)
Clinical pathway
The diagnosis of melanoma can take place in primary, secondary,
and tertiary care settings by both generalist and specialist health-
care providers. In the UK, people with concerns about a new or
changing lesion will usually present first to their general practi-
tioner (GP) or, less commonly, directly to a specialist in secondary
care, which could include a dermatologist, plastic surgeon, or other
specialist surgeon (such as an ear, nose, and throat (ENT) specialist
or maxillofacial surgeon), or ophthalmologist (Figure 5). Current
UK guidelines recommend that GPs should assess all suspicious
pigmented lesions presenting in primary care by taking a clinical
history and visually inspecting them using the revised seven-point
checklist (MacKie 1990). Clinicians should refer those with sus-
pected melanoma or cSCC for appropriate specialist assessment
within two weeks (Chao 2013; London Cancer Alliance 2013;
Marsden 2010; NICE 2015a). Evidence is emerging, however, to
suggest that excision ofmelanoma byGPs is not associatedwith in-
creased risk compared with outcomes in secondary care (Murchie
2017). In the UK, low-risk BCC are usually recommended for
routine referral, with urgent referral for those in whom a delay
could have a significant impact on clinical outcomes, for example
due to large lesion size or critical site (NICE 2015b). Appropriately
qualified generalist care providers increasingly undertake manage-
ment of low-risk BCCs in the UK, for example by excising low-
risk lesions (NICE 2010). Similar guidance is in place in Australia
(CCAAC Network 2008).
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Figure 5. Current clinical pathway for people with skin lesions.
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For referred lesions, the specialist clinician will also use history-
taking, inspection of the lesion (in comparison with other lesions
on the skin and usually in conjunction with dermoscopic exami-
nation), and palpation of the lesion and associated regional nodal
basins to inform a clinical decision. Ifmelanoma is suspected, then
urgent 2 mm excision biopsy is recommended (Lederman 1985;
Lees 1991); for cSCC, clinicians may consider predetermined sur-
gical margin excision or a diagnostic biopsy. BCC and pre-ma-
lignant lesions potentially eligible for non-surgical treatment may
undergo a diagnostic biopsy before initiation of therapy. Equiv-
ocal melanocytic lesions for which a definitive clinical diagnosis
cannot be reached may undergo surveillance to identify any lesion
changes that would indicate excisional biopsy or reassurance and
discharge for those that remain stable over a period of time.
Prior test(s)
The diagnosis of skin cancer is based on history-taking and clinical
examination. In the UK, this is typically undertaken at two deci-
sion points - first in the GP surgery where a decision is made to
refer or not to refer, and then a second time where a dermatologist
or other secondary care clinician makes a decision whether or not
to biopsy or excise. Visual inspection of the skin is on an iterative
basis, using both implicit pattern recognition (non-analytical rea-
soning) and more explicit ’rules’ based on conscious analytical rea-
soning (Norman 2009), the balance of which will vary according
to experience and familiarity with the diagnostic question. Various
attempts have been made to formalise the ’mental rules’ involved
in analytical pattern recognition for melanoma (Friedman 1985;
Grob 1998; MacKie 1985; MacKie 1990; Sober 1979; Thomas
1998); however, visual inspection for keratinocyte skin cancers re-
lies primarily on pattern recognition. Accuracy has been shown
to vary according to the expertise of the clinician. Some authors
have reported that primary care physicians miss over half of BCC
(Offidani 2002), and they misdiagnose a third (Gerbert 2000).
In contrast, an Australian study found that trained dermatologists
were able to detect 98% of BCC, but with a specificity of only
45% (Green 1988).
A range of technologies have emerged to aid diagnosis to reduce
the number of diagnostic biopsies or inappropriate surgical proce-
dures. Dermoscopy using a handheld microscope has become the
most widely used tool for clinicians to improve diagnostic accu-
racy of pigmented lesions, in particular for melanoma (Argenziano
1998; Argenziano 2012; Haenssle 2010; Kittler 2002), although
it is less well established for the diagnosis of BCC or cSCC. Three
reviews in this series have evaluated the diagnostic and compara-
tive accuracy of visual inspection and dermoscopy (Dinnes 2018a;
Dinnes 2018b, Dinnes 2018c).
Role of index test(s)
Used in conjunction with clinical or dermoscopic suspicion of
malignancy, or both, in pigmented lesions, HFUS may have a po-
tential role in patient management as an additional test to identify
lesions requiring excision. The status of current medical practice
and patient benefit formelanoma is particularly suited to improve-
ment by any cost-effective diagnostic imaging method that might
be developed, since early diagnosis that leads to complete exci-
sion of primary melanoma before metastatic spread almost always
results in a cure. The probability of metastases increases dramat-
ically with increasing depth of tumour invasion of the primary
melanoma (known as the Breslow thickness). This is assessed by
histological examination after excision but has the potential to be
assessed by imaging in vivo. One of the postulated advantages of
HFUS is its ability to rule out melanoma as a potential differen-
tial diagnosis, for example by identifying pigmented seborrhoeic
keratosis (a benign skin lesion).
Although the primary aim in diagnosing potentially life-threat-
ening conditions such as melanoma is to minimise false negative
diagnoses (to avoid delay to diagnosis and even death), a test that
can reduce false positive clinical diagnoses without missing true
cases of disease has clear patient and resource benefits. False-posi-
tive diagnoses not only cause unnecessary scarring from a biopsy
or excision procedure, but they also increase patient anxiety whilst
they await the definitive histological results and increase healthcare
costs as the number needed to remove to yield one melanoma di-
agnosis increases. Pigmented lesions are common, so the resource
implication for even a small increase in the threshold to excise
lesions in populations where melanoma rates are increasing, will
avoid a considerable healthcare burden to both patient and health-
care provider, as long as lesions that are not excised turn out to be
harmless.
Delay in diagnosis of a BCC as a result of a false-negative test is not
as serious as for melanoma because BCCs are usually slow-grow-
ing and very unlikely to metastasise. However, delayed diagnosis
can result in larger and more complex surgical procedures with
consequently greater morbidity. Very sensitive diagnostic tests for
BCC, on the other hand, may compromise on lower specificity
leading to a higher false-positive rate and an enormous burden
of skin surgery, so a balance between sensitivity and specificity is
necessary. As with melanoma, the consequences of falsely reassur-
ing a person with cSCC that they do not have skin cancer can
be serious and potentially fatal. Thus, a good diagnostic test for
cSCC should demonstrate high sensitivity and a corresponding
high negative predictive value. A test that can reduce false pos-
itive clinical diagnoses without missing true cases of disease has
patient and resource benefits. False-positive clinical diagnoses not
only cause unnecessary morbidity from the biopsy but could lead
to initiation of inappropriate therapies and also increase patient
anxiety.
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Studies have also evaluated HFUS as a method for non-invasive
measurement of melanoma thickness in vivo so that melanomas
can be excised with the appropriate margin in a single surgical
procedure as opposed to two separate procedures (Jasaitiene 2011;
Machet 2009; Meyer 2014). In addition to its optical B-mode
imaging cousin, Wang 2013 evaluated optical coherence tomog-
raphy, while Crisan 2013 studied its role in appropriate treatment
planning for BCC. There is potential for refining surgical proce-
dures, as well as increasing the use and efficacy of non-surgical
methods of treating BCC, if non-invasive imaging can be devel-
oped that allows confirmation of tumour clearance. However, this
review does not consider any of these uses.
Alternative test(s)
Doppler ultrasound, unlike B-mode ultrasound, measures moving
structures such as blood cells, as opposed to stationary tissues (
Kleinerman 2012), and it shows the relative speed of blood flow
as well as relative vessel size and density. In skin cancer, it can be
used in combination with B-mode HFUS and may have value
for staging or assessing the aggressiveness of malignancy due to
increased vascular proliferation.Doppler ultrasoundmay be useful
in preoperative staging due to correlation between the extent of
vascularisation and blood flow with Breslow thickness. As a stand-
alone technique, Doppler ultrasound is not useful to differentiate
skin cancers from benign lesions (Kleinerman 2012), so we do
not include it as an index test; however, its use in combination
with high-frequency ultrasound may be able to improve lesion
discrimination.
Cochrane DTA Reviews have assessed a number of other tests that
may have a role in the diagnosis of skin cancer as part of this series,
for example, visual inspection and dermoscopy (Dinnes 2018a;
Dinnes 2018b; Dinnes 2018c); reflectance confocal microscopy
(RCM) (Dinnes 2018d; Dinnes 2018e); optical coherence to-
mography (OCT) (Ferrante di Ruffano 2018a); and computer-as-
sisted diagnosis (CAD) techniques applied to various types of im-
ages, including those generated by dermoscopy, diffuse reflectance
spectrophotometry (DRS) and electrical impedance spectroscopy
(EIS) (Ferrante di Ruffano 2018b).
RCM andOCT are two alternative ways to achieve depth-resolved
optical reflectance imaging. To attain axial resolution, RCM uses
a very low numerical aperture with out-of-focus data suppression,
whileOCTuses interferometry to isolate optical reflections at a de-
fined echo time (conceptually similar to HFUS). They are emerg-
ing as non-invasive adjuncts to dermoscopy in a specialist setting,
and RCM can potentially serve as an alternative to dermoscopy
for skin cancer diagnosis (Edwards 2016).
RCM and OCT differ from each other in that RCM tends to use
a shorter wavelength (830 nm as opposed to 1305 nm for OCT)
and has considerably less penetration (RCM < 300 µm; OCT < 2
mm), poorer depth of focus (RCM 3 µm to 5 µm; OCT 1 mm),
and a more limited basic field of view (RCM basic 500 µm × 500
µm in the horizontal plane; OCT basic 6mm × 6mm) thanOCT,
but it has better lateral resolution (RCM 1 µm, cellular; OCT
7.5 µm, near cellular). They have similar axial resolution, however
(RCM 3 µm to 5 µm; OCT 5 µm), and both have fields of view
that are extendible by mechanical scanning and image mosaick-
ing, although for equivalent fields of view 3D imaging is much
faster with OCT (RCM for mosaicked field of view and stack >
10 min; OCT 6 cross-sectional frames per second, < 2 min for 6
mm × 6 mm × 2 mm volume). With RCM, the contrast for the
monochrome images produced is achieved by the variation of the
optical scattering properties within the skin when illuminated by
a near-infrared light. At a wavelength of 830 nm, the greatest con-
trast is achieved from melanin, so that RCM is recommended as
particularly useful for assessing pigmented lesions (Dinnes 2018d).
Similar to Doppler ultrasound but with higher resolution, vascu-
lar flow information can be extracted fromOCT images, allowing
the visualisation of neovascularisation, potentially enabling earlier
diagnosis of melanoma (Kokolakis 2012; Themstrup 2015).
CAD or artificial intelligence-based techniques use predefined al-
gorithms to process and manipulate acquired data to identify the
features that discriminate malignant from benign lesions. The use
of CAD-based techniques has potential for both reducing the sub-
jectivity of, and de-skilling, the diagnosis of skin lesions. Although
such techniques have most commonly been applied to digital der-
moscopy images (Esteva 2017; Rajpara 2009), they may be ap-
plied to several types of images or spectra (e.g. Wallace 2000).
For example, SIAscopy and MelaFind are based on diffuse re-
flectance spectrophotometry. DRS also uses optical reflectance, al-
beit not depth-resolved, but it distinguishes between lesion types
based on the lesion-average spectral shape and calibrated level of
reflected light for wavelengths continuously varying from the ul-
traviolet (320 nm) to the near infrared (1100 nm) with a high
spectral resolution (4 nm) (e.g. Marchesini 1992; Wallace 2000a).
The extension to imaging spectrophotometry (DRSi) to allow spa-
tial (dermoscopic) as well as spectral information to contribute to
the diagnosis, as described in Haddock 2003, has resulted in the
development of handheld DRSi units (Bish 2014). Researchers
have studied two such units with limited spectral capability in both
primary and secondary care settings: Moncrieff 2002 and Walter
2012 have evaluated SIAscopy, while Hauschild 2014, Monheit
2011 and Wells 2012 have assessed MelaFind. It is also possible
to combine DRSi with HFUS (Bamber 2007). Such approaches
remain under development.
The Nevisense system is based on electrical impedance spec-
troscopy (EIS). EIS measures a combination of resistance and ca-
pacitance of the tissue as a function of frequency of an alternat-
ing applied voltage. At high frequencies, conduction occurs easily
through all tissue components, including cells, but at low frequen-
cies current tends to flow only through the extracellular space. The
spectral shape is thus sensitive to cellular components and dimen-
sions, internal structure and cellular arrangements. The Nevisense
EIS system measures at multiple depths and at 35 frequencies log-
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arithmically distributed from 1.0 kHz to 2.5 MHz using a 5 mm
× 5 mm area electrode covered in tiny pins that penetrate into the
stratum corneum. Braun 2017 and Malvehy 2014 have evaluated
it, finding high sensitivity but low specificity for melanoma. Al-
though there is concern over a possible increase in needless excision
of benign atypical melanocytic lesions (Ceder 2016), this concern
is counterpoised against an indication of promise for reducing the
need for short-term sequential digital dermoscopy (Rocha 2017).
DRS and EIS have not been the subject of individual test reviews
due to an anticipated lack of data; however, where available, we
have includedCAD-based uses of these techniques in our review of
CAD for the detection of skin cancer (Ferrante di Ruffano 2018b).
Evidence permitting, we will compare the accuracy of available
tests in an overview of reviews, exploiting within-study compar-
isons of tests and allowing the analysis and comparison of com-
monly used diagnostic strategies where tests may be used alone or
in combination.
Rationale
Our series of reviews of diagnostic tests used to assist clinical diag-
nosis of skin cancer aims to identify the most accurate approaches
to diagnosis and provide clinical and policy decision-makers with
the highest possible standard of evidence on which to base de-
cisions. With increasing melanoma and basal cell carcinoma in-
cidence and the push towards the use of dermoscopy and other
high-resolution image analysis in primary care, the anxiety around
missing early malignant lesions needs to be balanced against the
risk of too many referrals, to avoid sending too many people with
benign lesions for a specialist opinion. It is questionable whether
all skin cancers picked up by sophisticated techniques, even in
specialist settings, help to reduce morbidity and mortality, and
there is concern that newer technologies run the risk of increas-
ing false-positive diagnoses. It is also possible that use of some
technologies, e.g. widespread use of dermoscopy in primary care
with little or no training, could actually result in harm by missing
melanomas if they are used as replacement technologies for tradi-
tional history-taking and clinical examination of the entire skin.
Many branches of medicine have noted the danger of such ’gizmo
idolatry’ amongst doctors (Leff 2008).
To date, the expense (in terms of both equipment and staff time)
and the need for specialised training have limited the use of tests
such as RCM. If shown to be sufficiently accurate, a test such as
HFUS could prove to be a relatively low-cost tool to assist in the
earlier diagnosis and better management of skin cancer.
This review follows a generic protocol that covers the full series
of Cochrane DTA Reviews for the diagnosis of melanoma and
keratinocyte skin cancers (Dinnes 2015a; Dinnes 2015b). The
Background and Methods sections of this review therefore use
some text that was originally published in the protocols (Dinnes
2015a; Dinnes 2015b), plus text that overlaps some of our other
reviews (Dinnes 2018a; Dinnes 2018b; Dinnes 2018c).
O B J E C T I V E S
To determine the diagnostic accuracy of high-frequency ultra-
sound to assist in the diagnosis of cutaneous invasive melanoma
and atypical intraepidermal melanocytic variants in adults.
To determine the diagnostic accuracy of high-frequency ultra-
sound to assist in the diagnosis of basal cell carcinoma in adults.
To determine the diagnostic accuracy of high-frequency ultra-
sound to assist in the diagnosis of cutaneous squamous cell carci-
noma in adults.
Secondary objectives
To determine the diagnostic accuracy of Doppler ultrasound plus
HFUS for the diagnosis of each of the three target conditions (cuta-
neous invasivemelanoma and atypical intraepidermalmelanocytic
variants, BCC or cSCC). We set out to address a range of poten-
tial sources of heterogeneity for investigation across our series of
reviews, as described in Appendix 4 and outlined in our generic
protocols (Dinnes 2015a; Dinnes 2015b); however, our ability to
investigate these was necessarily limited by the available data on
each individual test reviewed. Ultimately, we conducted no het-
erogeneity investigations for this review of HFUS.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included test accuracy studies that allow comparison of the
result of the index test with that of a reference standard, including
the following.
• Studies where all participants received a single index test
and a reference standard.
• Studies where all participants received more than one index
test and reference standard.
• Studies where participants were allocated (by any method)
to receive different index tests or combinations of index tests and
all received a reference standard (between-person comparative
studies (BPC)).
• Studies that recruited series of participants unselected by
true disease status (referred to as case series for the purposes of
this review).
• Diagnostic case-control studies that separately recruited
diseased and non-diseased groups (see Rutjes 2005).
• Both prospective and retrospective studies.
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• Studies where previously acquired clinical or dermoscopic
images were retrieved and prospectively interpreted for study
purposes.
We excluded studies from which we could not extract 2 × 2 con-
tingency data or if they included fewer than five melanoma, BCC
or cSCC cases or fewer than five benign lesions.
Studies available only as conference abstracts were excluded; how-
ever, attempts were made to identify full papers for potentially
relevant conference abstracts (Searching other resources).
Participants
We included studies in adults with lesions suspicious for skin can-
cer. We excluded studies that recruited only participants with ma-
lignant diagnoses and studies that compared test results in partic-
ipants with malignancy compared with test results based on ’nor-
mal’ skin as controls, due to the bias inherent in such compar-
isons (Rutjes 2006). We excluded studies in children and those
that clearly reported inclusion of more than 50% of participants
aged 16 and under.
Index tests
Studies evaluating HFUS alone or in combination with Doppler
ultrasound were eligible. HFUS was considered to have been eval-
uated if the centre (or median) frequency of the transmitted pulse
was at least 20 MHz.
Studies should ideally evaluate a predefined ’rule’ or algorithm
describing combinations of ultrasound characteristics that deter-
mine the presence or absence of melanoma, BCC or cSCC. How-
ever, as HFUS is in a relatively early phase of development, we
included studies if we could extract 2 × 2 contingency table data
based on the presence or absence of at least two ultrasound fea-
tures related to tissue morphology or acoustic properties, for ex-
ample echogenicity, homogeneity of appearance and definition of
margins. Studies attempting to quantify HFUS parameters were
also eligible for inclusion. There was no requirement for studies
to have explicitly set out to estimate the diagnostic accuracy of the
parameters assessed.
We made no exclusions according to test observer experience or
qualifications.
Target conditions
We defined the target conditions as the detection of:
• any form of invasive cutaneous melanoma or atypical
intraepidermal melanocytic variants (i.e. including melanoma in
situ or lentigo maligna);
• BCC (all subtypes);
• cSCC.
Reference standards
The ideal reference standard was histopathological diagnosis of the
excised lesion or biopsy sample in all eligible lesions. A qualified
pathologist or dermatopathologist should perform histopathol-
ogy. Ideally, reporting should be standardised, detailing a mini-
mumdataset including the histopathological features ofmelanoma
needed to determine the American Joint Committee on Cancer
(AJCC) Staging System (e.g. Slater 2014). We did not apply the
reporting standard as a necessary inclusion criterion but extracted
any pertinent information.
Partial verification (applying the reference test only to a subset of
those undergoing the index test) was of concern given that biopsy
or excisions are unlikely to be carried out for all clinically benign
lesions within a representative population sample. Therefore, we
accepted clinical follow-up of clinically benign lesions as an eligi-
ble reference standard, whilst recognising the risk of differential
verification bias (as misclassification rates of histopathology and
follow-up will differ) in our quality assessment of studies.
Additional eligible reference standards included cancer registry
follow-up and ’expert opinion’ with no histology or clinical fol-
low-up. Cancer registry follow-up is considered less desirable than
active clinical follow-up, as follow-up is not carried out within
the control of the study investigators. Furthermore, if participant-
based analyses as opposed to lesion-based analyses are presented,
it may be difficult to determine whether the detection of a ma-
lignant lesion during follow-up is the same lesion that originally
tested negative on the index test.
All of the above were considered eligible reference standards with
the following caveats.
• All study participants with a final diagnosis of the target
disorder must have a histological diagnosis, either subsequent to
the application of the index test or after a period of clinical
follow-up.
• At least 50% of all participants with benign lesions must
have either a histological diagnosis or clinical follow-up to
confirm benignity.
Search methods for identification of studies
Electronic searches
The Information Specialist (SB) carried out a comprehensive
search for published and unpublished studies. A single large liter-
ature search was conducted to cover all topics in the programme
grant (see Appendix 1 for a summary of reviews included in the
programme grant). This allowed for the screening of search results
for potentially relevant papers for all reviews at the same time.
A search combining disease related terms with terms related to
the test names, using both text words and subject headings was
formulated. The search strategy was designed to capture studies
evaluating tests for the diagnosis or staging of skin cancer. As the
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majority of records were related to the searches for tests for stag-
ing of disease, a filter using terms related to cancer staging and
to accuracy indices was applied to the staging test search, to try
to eliminate irrelevant studies, for example, those using imaging
tests to assess treatment effectiveness. A sample of 300 records that
would be missed by applying this filter was screened and the filter
adjusted to include potentially relevant studies. When piloted on
MEDLINE, inclusion of the filter for the staging tests reduced the
overall numbers by around 6000. The final search strategy, incor-
porating the filter, was subsequently applied to all bibliographic
databases as listed below (Appendix 5). The final search result was
cross-checked against the list of studies included in five systematic
reviews; our search identified all but one of the studies, and this
study was not indexed on MEDLINE. The Information Special-
ist devised the search strategy, with input from the Information
Specialist from Cochrane Skin. No additional limits were used.
We searched the following bibliographic databases to 29 August
2016 for relevant published studies.
• MEDLINE via OVID (from 1946).
• MEDLINE In-Process & Other Non-Indexed Citations via
OVID.
• Embase OVID (from 1980).
We searched the following bibliographic databases to 30 August
2016 for relevant published studies.
• the Cochrane Central Register of Controlled Trials
(CENTRAL; 2016, Issue 7) in the Cochrane Library;
• the Cochrane Database of Systematic Reviews (CDSR;
2016, Issue 8) in the Cochrane Library;
• Cochrane Database of Abstracts of Reviews of Effects
(DARE; 2015, Issue 2);
• CRD HTA (Health Technology Assessment) database,
2016, Issue 3; and
• CINAHL (Cumulative Index to Nursing and Allied Health
Literature via EBSCO from 1960).
We searched the followingdatabases for relevant unpublished stud-
ies using a strategy based on the MEDLINE search:
• CPCI (Conference Proceedings Citation Index), via Web of
Science™ (from 1990; searched 28 August 2016); and
• SCI Science Citation Index Expanded™ via Web of
Science™ (from 1900, using the ’Proceedings and Meetings
Abstracts’ Limit function; searched 29 August 2016).
We searched the following trials registers using the search terms
’melanoma’, ’squamous cell’, ’basal cell’ and ’skin cancer’ combined
with ’diagnosis’:
• Zetoc (from 1993; searched 28 August 2016).
• The US National Institutes of Health Ongoing Trials
Register (www.clinicaltrials.gov); searched 29 August 2016.
• NIHR Clinical Research Network Portfolio Database (
www.nihr.ac.uk/research-and-impact/nihr-clinical-research-
network-portfolio/); searched 29 August 2016.
• The World Health Organization International Clinical
Trials Registry Platform ( apps.who.int/trialsearch/); searched 29
August 2016.
We aimed to identify all relevant studies regardless of language
or publication status (published, unpublished, in press, or in
progress). We applied no date limits.
Searching other resources
We screened relevant systematic reviews identified by the searches
for their included primary studies and included any missed by our
searches.We checked the reference lists of all included papers, and
subject experts within the author team reviewed the final list of
included studies.We did not perform electronic citation searching.
Data collection and analysis
Selection of studies
At least one author (JDi or NC) screened titles and abstracts, dis-
cussing and resolving any queries by consensus. A pilot screen of
539 MEDLINE references showed good agreement (89% with a
kappa of 0.77) between screeners. We included primary test ac-
curacy studies and test accuracy reviews (for scanning of reference
lists) of any test used to investigate suspected melanoma, BCC, or
cSCC at initial screening. Both a clinical reviewer (from a team
of 12 clinician reviewers) and a methodologist reviewer (JDi or
NC) independently applied inclusion criteria (Appendix 6) to all
full text articles, resolving disagreements by discussion or consul-
tation with a third party if no consensus could be reached (JDe,
CD, HW, or RM). We contacted authors of eligible studies when
studies presented insufficient data to allow for the construction of
2 × 2 contingency tables.
Data extraction and management
One clinical (as detailed above) and one methodologist reviewer
(JDi,NCor LFR) independently extracted data concerning details
of the study design, participants, index test(s) or test combinations
and criteria for index test positivity, reference standards, and data
required to populate a 2 × 2 diagnostic contingency table for each
index test using a piloted data extraction form. We extracted data
at all available index test thresholds, resolving disagreements by
discussion or in consultation with a third party, in case no con-
sensus could be reached (JDe, CD, HW, or RM).
We contacted authors of included studies in case of missing infor-
mation related to the diagnostic threshold or target condition (in
particular to allow the differentiation of invasive cancers from in
situ variants). We contacted authors of conference abstracts pub-
lished from2013 to 2015 to ask whether full data were available. If
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we could not identify a full paper, we marked conference abstracts
as ’pending’, and we will revisit them in a future review update.
Dealing with multiple publications and companion papers
Where we identified multiple reports of a primary study, we max-
imised yield of information by collating all available data. Where
there were inconsistencies in reporting or overlapping study pop-
ulations, we contacted study authors for clarification in the first
instance. If this contact with authors was unsuccessful, we used
the most complete and up-to-date data source where possible.
Assessment of methodological quality
We assessed risk of bias and applicability of included studies using
the QUADAS-2 checklist (Whiting 2011), tailored to the review
topic (see Appendix 7). We piloted the modified QUADAS-2
tool on a small number of included full-text articles. One clinical
(as detailed above) and one methodologist reviewer (JDi, NC or
LFR) independently assessed risk of bias and applicability for the
remaining studies, solving any disagreements by discussion or in
consultation with a third party (JDe, CD, HW, or RM). We did
not contact authors to clarify methodological uncertainties. The
methodological quality assessment was therefore of the study as
reported and may not always fully reflect the quality of the study
as conducted.
Statistical analysis and data synthesis
Due to paucity of data and between-study heterogeneity in the
ultrasound characteristics and measurements that we investigated,
we did not undertake a meta-analysis for this review. For the di-
agnosis of melanoma, we considered any BCCs or invasive cSCCs
that were positively identified in the ’disease negative’ group to be
true negative test results rather than as false positives, on the basis
that excision of such lesions would be a positive outcome for the
participants concerned. For the diagnosis of BCC, however, we
considered any melanomas or cSCCs that were positively identi-
fied in the ’disease negative’ group to be false positive results. We
made this decision on the basis that the clinical management of a
lesion considered to be a BCC might be quite different to that for
a melanoma or cSCC and could potentially lead to a negative out-
come for the participants concerned, for example if participants
initiated a treatment other than excision.
We plotted estimates of sensitivity and specificity on coupled forest
plots for each characteristic or threshold under consideration. Our
unit of analysis was the lesion rather than the patient, as this was
themost commonway in which the primary studies reported data.
As most participants have only one lesion to consider at a time,
and as both index tests and reference standards are defined at the
lesion level, the results are likely to be similar to those obtained
at a participant level. We included data for Doppler ultrasound
only if reported in combination with HFUS tissue morphological
or acoustic property imaging; we did not evaluate the accuracy of
Doppler ultrasound alone.
Investigations of heterogeneity
We examined heterogeneity between studies by visually inspecting
the forest plots of sensitivity and specificity. We did not identify
enough studies to allow meta-regression to investigate potential
sources of heterogeneity.
Sensitivity analyses
We did not conduct sensitivity analyses due to lack of data.
Assessment of reporting bias
Because of uncertainty about the determinants of publication bias
for diagnostic accuracy studies and the inadequacy of tests for de-
tecting funnel plot asymmetry (Deeks 2005), we did not perform
any tests to detect publication bias.
R E S U L T S
Results of the search
We identified and screened a total of 34,517 unique references for
inclusion.Of these, we reviewed1051 full-text papers for eligibility
for any one of the suite of reviews of tests to assist in the diagnosis
of melanoma or keratinocyte skin cancer. Of the 1051 full-text
papers assessed, we excluded 848 and included 203 publications
across all reviews in our series (see Figure 6 PRISMA flow diagram
of search and eligibility results).
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Figure 6. PRISMA flow diagram.
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Of the 41 studies tagged as potentially eligible for this review of
HFUS, we included 6. One study could not be obtained from the
British Library (Nitsche 1992). Exclusions were due to the use of:
• ineligible index tests (17 studies: 9 evaluations of Doppler
ultrasound, 7 studies using ultrasound transducers with centre
frequency less than 20 MHz, and one evaluating the accuracy of
a single feature on ultrasound);
• ineligible study populations (4 studies: 2 recruiting only
malignant lesions, and 2 including lesions that were not
suspicious for skin cancer);
• ineligible definition of the target condition (8 studies: 4
identifying lesion thickness, 1 focusing on surgical margins, 2
investigating melanoma metastases, and 1 considering lesions
such as dermatofibroma or Bowen’s disease to be disease
positive); and
• inadequate sample size (1 study).
The Characteristics of excluded studies provides a list of the 34
studies excluded from this review with reasons for exclusion, and
a list of all studies excluded from the full series of reviews is also
available as a separate pdf (please contact skin.cochrane.org for a
copy of the pdf ). We contacted the authors of one publication for
the purposes of this review; however, they were unable to provide
the additional data needed to allow the study to be included.
This review reports on a total of six cohorts of lesions published in
six study publications and providing 29 datasets: 20 formelanoma
and 9 for BCC. We did not identify data relating to the diagnosis
of cSCC.
Studies included four case series of patients, either with pig-
mented lesions (Bessoud 2003; Clement 2001; Dummer 1995),
or lesions described as suspicious for melanomas or BCC (Lassau
1997). Moreover, we found two case-control type studies that in-
cluded pigmented lesions with specific confirmed diagnoses of
melanoma, seborrhoeic keratosis or benign naevi (Harland 2000;
Rallan 2007). The Bessoud 2003 paper is from the same institu-
tion and has overlapping authorship with Lassau 1997, and there
may have been an overlap in study participants. Only Rallan 2007
clearly described the basis for referral or selection for ultrasound
examination, randomly selecting lesions referred from primary
care due to suspicion of melanoma. Clement 2001 described the
clinical diagnosis as ’hesitant’ for more than half of included le-
sions, but none of the other studies gave any indication as to the
equivocal nature or difficulty of diagnosis of the lesions included.
The number of included patients ranged from 70 to 160 (reported
in four studies) and lesions from 54 to 792. Only three studies
reported participant characteristics such as age and gender.
All studies apart from Clement 2001, which focused primarily on
the detection of BCC, reported data allowing the calculation of the
accuracy of ultrasound for the detection of melanoma; two other
studies also report data for detection of BCC (Dummer 1995;
Lassau 1997). The prevalence of melanoma in the study samples
ranged from 14% to 58%, and it appeared to be restricted to in-
vasive melanoma in Dummer 1995 and Lassau 1997. The preva-
lence of BCC was 8% (Dummer 1995), 17% (Clement 2001),
and 49% (Lassau 1997). In all studies apart from Lassau 1997
and Bessoud 2003, seborrhoeic keratosis made up at least 25% of
the disease negative groups, and it was as high as 66% in Harland
2000, which studied seborrhoeic keratosis versus melanoma.
All six studies used 20 MHz ultrasound scanners with axial reso-
lutions of 50 µm to 80 µm. Lateral resolutions ranged from about
100 µm in Bessoud 2003, Clement 2001, Lassau 1997 and Rallan
2007 to 300 µm in Harland 2000. Typically it was not clear how
authors obtained the resolution values, and based on the example
images in the papers, the instrumentation employed seemed to
vary greatly in terms of other diagnostically important imaging
performance properties such as signal dynamic range and signal-
to-noise level, which trialists did not report. In some cases such
performance appeared to be poor, providing little or no lesion in-
ternal detail compared with similar lesions on other systems. None
of the studies described the qualifications or experience of the clin-
ician carrying out and interpreting the ultrasound, and none re-
ported whether the clinical or dermoscopic diagnosis of the lesion
was available to aid test interpretation.
Three studies explicitly set out to establish the diagnostic accu-
racy of HFUS for the differentiation of melanomas from other
skin lesions (Bessoud 2003; Harland 2000; Rallan 2007); the re-
maining three studies did not set out to evaluate test accuracy
but presented data for the presence or absence of particular ultra-
sound characteristics that could be extracted into 2 × 2 contin-
gency tables (Clement 2001; Dummer 1995; Lassau 1997). Qual-
itative HFUS characteristics that were considered were related to
the echogenicity and homogeneity of appearance and to definition
of margins (Bessoud 2003; Clement 2001; Dummer 1995; Lassau
1997). Four studies presented data for qualitative assessment of
the presence or absence of particular structural characteristics (in-
cluding echogenicity, homogeneity of appearance and definition
of margins) on the HFUS image either alone (Dummer 1995;
Lassau 1997; Clement 2001; Bessoud 2003) or in combination
with Doppler ultrasound assessment of vascularity (Lassau 1997;
Clement 2001; Bessoud 2003).
The remaining two studies examined different approaches to
quantitatively interpret ultrasound findings. Harland 2000 at-
tempted to classify lesions based on objective quantifications of
the extent of ultrasound shadowing and the strength of the ultra-
sound entry echo to differentiate between melanoma and sebor-
rhoeic keratosis, based on the dermal echogenicity ratio (DER) and
presence of a thickened entry echo line (EEL), respectively. Rallan
2007 further developed this work with a prototype 3D HFUS
C-scan and reflex transmission imaging system to evaluate these
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features and make ultrasound images easier for dermatologists to
interpret. This method produces three en face ultrasound images:
a reflex transmission image (RTI), a lesional backscatter image
(LBI) and an entry echo image (EEI), which relate to objectively
quantified lesion attenuation properties, intralesional sound re-
flection and surface sound reflectance characteristics, respectively.
For each image, investigators estimated two quantitative features
(contrast and heterogeneity) and compared them between lesion
groups (melanoma versus seborrhoeic keratosis, and melanoma
versus other benign pigmented lesions). Mean RTI contrast, LBI
relative heterogeneity, andEEI relative heterogeneitywere each sig-
nificantly different between melanoma and seborrhoeic keratosis
and betweenmelanoma and benign naevi; these three features were
combined using an ’or’ rule with specificity estimated at 100%
sensitivity (Rallan 2007). Authors reported the required values for
each of the three parameters to be considered ’positive’ graphically
but not numerically (Rallan 2007).
Three studies using qualitative HFUS interpretation reported
the exclusion of lesions not visualised by ultrasound: 10% in
Lassau 1997 (including 3 melanomas), 12% in Bessoud 2003
(including for 5 melanomas), and 22% in Clement 2001 (in-
cluding 5 melanomas). In all studies the reference standard di-
agnosis was made by histology alone (i.e. all lesions either ex-
cised or biopsied). Histological diagnosis was based on excisional
biopsy (Dummer 1995), surgical resection or excision (Lassau
1997; Bessoud 2003; Harland 2000; Rallan 2007), and either ap-
proach (Clement 2001).
Methodological quality of included studies
Figure 7 and Figure 8 summarize the overall methodological qual-
ity of all six included studies.
Figure 7. Risk of bias and applicability concerns graph: review authors’ judgements about each domain
presented as percentages across included studies
21High-frequency ultrasound for diagnosing skin cancer in adults (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Figure 8. Risk of bias and applicability concerns summary: review authors’ judgements about each domain
for each included study
Two studies were at high risk of bias for participant selection due
to their selective inclusion of participants with particular histolog-
ical lesion types (Harland 2000; Rallan 2007). Five studies did not
clearly describe participant recruitment as random or consecutive,
and four did not clearly report any exclusion criteria. We judged
one study as being of low concern for applicability of participants
and setting (Clement 2001). We deemed four studies as being of
high and one, Dummer 1995, as being of unclear concern for ap-
plicability of participants due to unrepresentative patient samples
(Harland 2000; Lassau 1997; Rallan 2007), inclusion of multiple
lesions per patient (Bessoud 2003), or providing insufficient in-
formation on which to make a judgement (Dummer 1995). All
studies included only lesions selected for excision.
Only one study was at low risk of bias in the index test domain.
We considered that ultrasound was interpreted prior to the his-
tological reference standard in all studies, but only one clearly re-
ported prior specification of the diagnostic threshold or ultrasound
characteristics used to differentiate melanomas from other lesions
(Bessoud 2003). The other studies were all rated as high risk for
this item, either because they did not clearly set out to examine the
accuracy of HFUS (Clement 2001; Dummer 1995; Lassau 1997),
or because they deliberately set their thresholds to achieve 100%
sensitivity (Harland 2000; Rallan 2007). Two studies caused high
concern around the applicability of the index test: Harland 2000
due to the use of a prototype ultrasound device and Rallan 2007
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due to a relatively experimental approach to the index test. All
studies clearly described the criteria or diagnostic thresholds used,
but no study provided information on the expertise and experi-
ence of the test operator or sonographer.
All studies reported the use of an acceptable reference standard, but
only one clearly reported blinding of the reference standard to the
ultrasound result (Harland 2000), andnone of the studies reported
blinding to the referral diagnosis (based on clinical examination
or dermoscopy). For the applicability of the reference standard, no
study reported using expert diagnosis to provide the final diagnosis
of any lesion, and only one reported histopathology interpretation
by an experienced histopathologist or by a dermatopathologist.
All studies used the same reference standard in all participants,
and two were unclear on the interval between the application of
the index test and excision for histology (Bessoud 2003; Harland
2000). Three studies reported exclusions due to lesions not being
visualised on ultrasound (Bessoud 2003; Clement 2001; Lassau
1997); however, all three provided a breakdown of the final histo-
logic diagnosis for these lesions, so we judged them as being at low
risk on the flow and timing domain. Three studies did not report
any exclusions due to lack of visualisation of lesions (Dummer
1995; Harland 2000; Rallan 2007). Two of these allowed the ul-
trasound features employed to be measured regardless of whether
the lesions were visualised or not, and we did not judge them as
being at low risk of bias on this item (Harland 2000; Rallan 2007).
Findings
Lack of data, combined with between-study variations in popu-
lations, ultrasound techniques and characteristics, and measure-
ments investigated precluded meta-analysis. We summarise study
results below according to target condition: melanoma or BCC.
We found no data on the identification of cSCC. Appendix 8 pro-
vides summary details, while forest plots of available study data
are in Figure 9 (HFUS for differentiation of melanoma), Figure
10 (for HFUS combined with Doppler US for melanoma) and
Figure 11 (HFUS for differentiation of BCC).
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Figure 9. Forest plot of tests for differentiation of melanoma from other lesions using combinations of
HFUS characteristics and quantitative measurements of HFUS outputs
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Figure 10. Forest plot of tests for the differentiation of melanoma from other lesions using HFUS and
Doppler US
Figure 11. Forest plot of tests for the differentiation of BCC from other lesion types using HFUS
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Detection of invasive melanoma or atypical
intraepidermal melanocytic variants
Combinations of subjective assessments of HFUS features
Wewere able to extractHFUS data related to the qualitative assess-
ment of the presence or absence of different combinations of le-
sions’ morphological and structural characteristics as an indicator
of melanoma from three studies (Bessoud 2003; Dummer 1995;
Lassau 1997), one of which set out to assess the diagnostic accu-
racy of these characteristics for the differentiation of melanoma
from other lesions (Bessoud 2003; Figure 9; Appendix 8).
Dummer 1995 reported recruitment of a series of 792 pigmented
lesions with a range of final diagnoses including melanoma (14%),
BCC (8%), benign naevi (39%), seborrhoeic keratosis (27%), and
dermatofibroma or angioma (13%). Sensitivities and specificities
estimated from the data ranged from 64% (95% CI 60% to 87%)
to 83% (95% CI 75% to 90%) for homogenous and hypoechoic
lesions and from 22% (95% CI 19% to 26%) to 91% (95% CI
84% to 95%) for hypoechoic lesions with sharp lateral margins.
For each of the combinations of characteristics examined in this
study, a number of BCCs were found to be ’test positive’, i.e. dis-
playing the characteristics under consideration. As per our proto-
col, we reclassified these false positive BCCs as true negative test
results (increasing specificity) on the basis that a positive test result
leading to excision of the BCCs would not be a negative patient
outcome. The number of BCCs that we artificially reclassified as
true negative despite the presence of the HFUS image features of
interest ranged from 5 (for echo-poor lesions with homogenous
internal echoes) to 57 (for echo-poor lesions with sharp basal mar-
gins).
Bessoud 2003 and Lassau 1997 presented data for the presence of
hypoechoic, homogenous, well-defined lesions, as well as results
for Doppler ultrasound that could be combined with HFUS data.
Bessoud 2003 included a series of 114 pigmented lesions (7 of
which didnot undergoDoppler ultrasound); included lesionswere
primarily invasive melanomas (57%) or benign naevi (29%) with
smaller percentages of BCC (4%), seborrhoeic keratosis (4%) and
other benign lesions. Lassau 1997 included 70 lesions clinically
suspected of being either melanoma (n = 38) or BCC (n = 32).
Visualisation of 7 lesions on ultrasound was not possible, so in-
vestigators excluded them, leaving 19 (27%) invasive melanoma,
31 (44%) BCC, 1 neurosarcoma, and 12 (17%) benign naevi (3
of the 7 lesions not visualised on HFUS were melanomas).
The sensitivity of the combinedHFUS characteristicswas 100% in
both studies (lower limits of the 95%CIs for sensitivities were 94%
in Bessoud 2003 (114 lesions, 65 melanomas) and 82% in Lassau
1997 (63 lesions, 19 melanomas)), with specificities of 33% (95%
CI 20% to 48%) and 73% (95% CI 57% to 85%), respectively.
Excluding BCCs from Lassau 1997 resulted in a specificity of 8%
(95% CI 0% to 36%; 32 lesions; 19 melanomas), the 12 benign
naevi all being considered hypoechoic, homogenous and well de-
fined. Both studies reported all BCCs as ’negative’ on ultrasound,
that is, with an absence of investigated characteristics (Bessoud
2003; Lassau 1997). Both studies also reported five melanomas
amongst the lesions not visualised by ultrasound (Appendix 8).
Combinations of subjective assessments of HFUS features
with Doppler US
Using data presented in Lassau 1997 for the presence of hypoe-
choic, homogenous, and well-defined lesions on HFUS with the
presence of intratumoural vessels on Doppler ultrasound (on an
either/or basis) makes no difference to the sensitivity and speci-
ficity achieved using HFUS alone for discriminating between in-
vasive melanoma (n = 19) and all other included lesions (n =
44). Only three melanomas (already picked up as test positive on
HFUS) displayed any evidence of vascularity onDoppler (sensitiv-
ity 100%, 95% CI 82% to 100%; specificity 73%, 95% CI 57%
to 85%; Figure 10). The HFUS and Doppler characteristics can
be combined on an ’and’ basis for both Bessoud 2003 and Lassau
1997, with lesions that were hypoechoic, homogenous, well de-
fined and exhibited intralesional vessels on Doppler being consid-
ered test positive. Thus, sensitivities were 34% (95% CI 22% to
47%; n = 65 melanomas) and 16% (95% CI 3% to 40%; n =
19 melanomas), respectively, with specificities of 100% (95% CI
92% to 100%) for both studies (number of benign lesions: 45 and
44 respectively).
Quantitative assessment of HFUS features
Two studies reported quantitative assessments of the ultrasound
image using the strength and heterogeneity of ultrasound shadow-
ing and the strength and heterogeneity of the ultrasound surface
entry echo (Harland 2000; Rallan 2007). Both studies included
only melanoma (n = 19 and n = 14 in Harland 2000 and Rallan
2007, respectively), melanoma in situ (n = 6 and n = 11), benign
naevi (n = 15 and n = 38) or seborrhoeic keratosis (n = 29 and
n = 24). The main comparison in Harland 2000 was between
melanoma and seborrhoeic keratosis (benign naevi excluded). Set-
ting the DER at < 3 to ensure sensitivity of 100% produced a
specificity of 79% (95% CI 60% to 92%); the absence of an EEL
resulted in sensitivity of 96% (95% CI 80% to 100%) and speci-
ficity 90% (95%CI 73% to 98%) for the same comparison. Com-
bining the two characteristics on an either/or basis (such that sen-
sitivity was 100%) increased specificity to 93% (95% CI 77% to
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99%) for discrimination of melanoma from seborrhoeic keratosis
(Figure 9). Of the 15 benign naevi in this study, 6 were reported to
have characteristics associated with EEL enhancement (or EEE),
suggesting that 9 would be considered ’test positive’ (absence of an
EEL); inclusion of these lesions as disease negative would reduce
the observed specificity.
Rallan 2007, on a prototype 3D HFUS C-scan with reflex trans-
mission imaging, found significant differences in the mean val-
ues of RTI contrast, LBI relative heterogeneity, and EEI relative
heterogeneity between melanoma and seborrhoeic keratosis and
between melanoma and benign naevi. When these three features
were combined using an ’or’ rule with sensitivity for melanoma
discrimination of 100% (95% CI 86% to 100%), the resulting
specificity was 65% (95% CI 51% to 76%; Figure 9).
Detection of BCC
Combinations of subjective assessments of HFUS features
Three studies reported data that could be used to derive the ac-
curacy of ultrasound characteristics for BCC: Clement 2001 and
Dummer 1995 in series of pigmented lesions, and Lassau 1997
in lesions suspicious for either melanoma or for BCC. Dummer
1995 and Lassau 1997 also reported data for melanoma. None of
the three studies set out to establish the accuracy of the reported
ultrasound characteristics. Clement 2001 included a series of 176
pigmented lesions, 38 of which were not visualised on ultrasound
(including 5 melanomas); the remaining 138 lesions included one
invasive melanoma, 23 (17%) BCC, 61 (44%) benign naevi, and
29 (21%) seborrhoeic keratoses, amongst others.
Using hypoechoic and homogenous appearance as a positive indi-
cator for BCC, sensitivity was 91% (95% CI 72% to 99%) and
specificity 14% (95% CI 8% to 22%) for Clement 2001 (138
lesions; 23 BCC), while they were 8% (95% CI 3% to 17%) and
54% (95% CI 50% to 57%), respectively, in Dummer 1995 (792
lesions; 65 BCC) (Figure 11).
Considering lesions that were hypoechoic and well defined as pos-
itive for BCC resulted in sensitivity of 83% (95%CI 61% to 95%)
and specificity 32% (95% CI 24% to 42%) in Clement 2001.
Dummer 1995 reported numbers of lesions with sharp basal mar-
gins and with sharp lateral margins. Considering lesions that were
hypoechoic with sharp basal margins as positive for BCC resulted
in sensitivity of 86% (95% CI 75% to 93%) and specificity of
20% (95% CI 17% to 23%); considering lesions that were hypoe-
choic with sharp lateral margins as positive for BCC resulted in
sensitivity of 42% (95% CI 29% to 54%) and specificity of 13%
(95% CI 11% to 16%).
Finally, data from Lassau 1997 could be derived to consider hy-
poechoic, homogenous and well-defined lesions as BCC (i.e. the
same characteristics previously considered to be positive indica-
tors for melanoma); this combination resulted in sensitivity of 0%
(95% CI 0% to 11%) and specificity of 3% (95% CI 0% to 16%)
(63 lesions; 31 BCCs; Figure 11). All BCCs were reportedly hy-
poechoic but with a heterogeneous echostructure and lateral ex-
tensions with irregular margins, i.e. negative on two of the char-
acteristics considered (Lassau 1997). If one instead considers the
presence of a heterogeneous echostructure and lateral extensions
with irregular margins to be positive indicators of BCC (i.e. revers-
ing the 2 × 2 contingency table), the resulting sensitivity is 100%
(95% CI 89% to 100%) and specificity 97% (95% CI 84% to
100%), with no melanomas and none of the benign naevi dis-
playing these characteristics. Bessoud 2003 also reported all four
included BCCs to be heterogenous and poorly defined; however,
a further 12 lesions including keratosis, melanosis and neurosar-
coma also demonstrated these characteristics.
Combinations of subjective assessments of HFUS features
with Doppler US
Two of the studies reporting data for BCC also employedDoppler
ultrasound in combination with HFUS (Clement 2001; Lassau
1997). Lassau 1997 allowed extraction of accuracy data only for
the detection of melanoma (melanoma versus benign naevi), while
for Clement 2001, consideration of lesions that were hyperechoic
on HFUS and displaying vascularity on Doppler produced a sen-
sitivity of 0% (95%CI 0% to 15%) and a specificity of 89% (95%
CI 81% to 94%). Considering the absence of these characteris-
tics as indicative of BCC (i.e. hypoechoic with no vascularity on
Doppler) would reverse these estimates, giving sensitivity of 100%
and specificity of 11%.
Investigations of heterogeneity
We were unable to undertake formal investigations of heterogene-
ity due to insufficient study numbers.
D I S C U S S I O N
Summary of main results
This review aimed to assess the accuracy of high-frequency ul-
trasound as an aid to diagnosing melanoma, BCC and cSCC in
adults. We did not identify any eligible data on cSCC. We in-
cluded six studies evaluating high-frequency ultrasound, three of
which also evaluated Doppler ultrasound (Summary of findings).
Studies were generally poorly reported, so we could not clearly
judge methodological quality and applicability of findings; this
was in part due to the fact that half of the studies did not set out
to establish test accuracy. We noted particularly high concerns in
regard to the selection of study participants, with high proportions
of malignant lesions and an unrepresentative spectrum of disease
in the disease-negative groups. Authors did not always describe
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the clinical pathway and referral process for ultrasound imaging
well. All studies used 20 MHz ultrasound devices at a range of
resolutions and a number of different qualitative and quantitative
thresholds, some of which were clearly data driven or not pre-
specified. Half the studies (all using qualitative or subjective as-
sessments of HFUS images) excluded a considerable proportion
of lesions because they were not visualised by ultrasound. It is not
clear from these studies whether this should be considered a fail-
ure of the test or whether the lack of visualisation of a lesion on
HFUS provides further diagnostic information that may assist in
the differential diagnosis. Studies applying quantitative interpre-
tations of HFUS allowed some ultrasound features to be measured
regardless of lesion visibility. Authors provided no information re-
garding the clinicians undertaking and interpreting the tests, lim-
iting the generalisability of results particularly for those relying on
qualitative interpretation of HFUS features. The final diagnoses
were established by histology in all studies; only one study reported
blinding to the ultrasound result or referral diagnosis. Sources of
heterogeneity included patient selection, ultrasound techniques,
test thresholds, prior testing and blinding.
For the detection of melanoma, derived sensitivities were at least
83% (95% CI 75% to 90%), with the combination of three qual-
itative features (lesions appearing hypoechoic, homogenous and
well defined) and quantitative assessments of images demonstrated
100% sensitivity in four studies (the widest 95% CI being 80% to
100%), although in two of these the decision thresholds were de-
liberately set to achieve 100% sensitivity in order to discover result-
ing specificity. Between three and five melanomas were amongst
the lesions not visualised by the HFUS in three studies, with no
index test ’failures’ reported by the two studies assessing quantita-
tive metrics. Specificities varied from 8% (95% CI 0% to 36%) to
73% (95% CI 57% to 85%) for qualitative characteristics, all of
which included BCC in the disease-negative group, which tends
to increase specificity, and from 65% (95% CI 51% to 76%) to
90% (95% CI 73% to 98%) for quantitative measurements, none
of which included BCC in the disease-absent group. For the de-
tection of BCC, sensitivities and specificities were highly variable,
making summary statements difficult. One study suggested that
the presence of heterogeneity and poorly defined margins might
differentiate BCCs from melanomas and benign naevi, although
another identified other lesions demonstrating similar character-
istics that might limit their usefulness in a more widely defined
population.
Strengths and weaknesses of the review
The strengths of this review include an in-depth and comprehen-
sive electronic literature search, systematic reviewmethods includ-
ing double extraction of papers by both clinicians and methodol-
ogists, and contact with authors to allow study inclusion or clarify
data. We planned a clear analysis structure to allow estimation of
test accuracy in different study populations, and we undertook a
detailed and replicable analysis of methodological quality.
The main concerns for the review arise from the poor reporting of
primary studies and the fact that the studies were not all designed
as test accuracy studies; in half of included studies, data to al-
low the estimation of sensitivity and specificity were derived from
the information on image descriptions presented by the study au-
thors. All three studies using qualitative interpretation of HFUS
reported that they had to exclude a number of lesions (including
some melanomas) because they could not be visualised, resulting
in an over-estimation of sensitivity for the characteristics assessed.
However, two of the remaining studies using quantitative HFUS
metrics and methodology allowed inclusion of all lesions regard-
less of their visualisation.
When estimating accuracy for the diagnosis of melanoma, we
classed any correctly identified BCCs as true negative results as
opposed to false positives, on the basis that removal of a BCC in
the attempt to identify melanomas would not be a negative conse-
quence of the test. This will have the effect of increasing specificity
compared to studies excluding BCCs. When estimating accuracy
for the diagnosis of BCC, however, we considered any other skin
cancers that were incorrectly identified as BCC (e.g. melanomas or
cSCCs) to be false positive results, as the subsequent management
of a BCC can be quite different to that of a melanoma or SCC,
and it is important that a test can accurately differentiate between
malignancies.
Applicability of findings to the review question
The data included in this review came from preliminary ex-
ploratory studies and are unlikely to be generally applicable to pre-
dicting the diagnostic accuracies that would be expected in stan-
dard clinical practice, where people present with a broad range
of different lesion types. Narrow definitions of the eligible study
populations, lack of clarity regarding the patient pathway and any
prior testing, and wide variation in the type and performance of
the HFUS equipment employed as well as in the method used for
image feature scoring, restrict generalisation and applicability. It
is not always clear whether the particular test methods used could
be transferred to a clinical setting.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
We could not produce any summary estimates of test accuracy
to answer the research question for this review. High-frequency
ultrasound may prove to be an additional tool to assist in the dif-
ferentiation of melanoma from other lesions; however, the current
evidence is based on participants with highly selected lesion types,
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and it is unclear how their results would translate in clinical prac-
tice. The lack of visualisation of lesions on HFUS is potentially
a major disadvantage unless the lack of visualisation has a clear
interpretation that can be used to inform management decisions,
clinicians can employ ultrasound metrics that do not depend on
lesion visualisation, or ultrasound visualisation can be improved
with equipment development. Given the between-study hetero-
geneity, unclear to low methodological quality and applicability
of findings, and limited volume of evidence, we can draw no im-
plications for practice. The main value of the preliminary studies
included in this review may be to provide guidance on the possi-
ble components of rules for diagnosing melanoma or BCC using
HFUS that will require further evaluation.
Implications for research
Prospective evaluation of high-frequency ultrasound added to vi-
sual inspection and dermoscopy alone in a standard health care
setting would be required for a full and proper evaluation of ac-
curacy. A clearly defined and representative population of partic-
ipants with a range of different lesion types is needed to estab-
lish the participant groups to whom study results can be applied
in practice. HFUS technology continues to be developed, so it is
important that current equipment is employed, using compatible
systems across centres, appropriate harmonisation in cross-centre
training and - where possible - objective quantitative diagnostic
image features so as to minimise exclusions (due to lack of visual-
isation) and interobserver variability.
Prospective recruitment of a consecutive series of participants,
with double-blinding between test interpretation and the refer-
ence standard diagnosis, and with pre-specified and clearly de-
fined diagnostic rules for determining the presence or absence of
disease are all necessary and easy to achieve. Systematic follow-
up of non-excised lesions avoids over-reliance on a histological
reference standard and allows results to be more generalisable to
routine practice. A standardised approach to diagnosis and clear
identification of the qualifications and level of observer training
and experience required to achieve good results is also required.
A multi-centred approach would allow confirmation that results
are replicable across centres and that the technology can be im-
plemented across a health service. Any future research study needs
to be clear about the diagnostic pathway followed by study par-
ticipants prior to study enrolment, and reporting should conform
to the updated Standards for Reporting of Diagnostic Accuracy
(STARD) guideline (Bossuyt 2015).
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Bessoud 2003
Study characteristics
Patient sampling Study design: case series
Data collection: prospective
Period of data collection: not reported; 4-year period
Country: France
Patient characteristics and set-
ting
Inclusion criteria: patients with pigmented skin lesions referred from theDermatologyDepartment
to the Ultrasound Unit
Setting: secondary
Prior testing: referred from Dermatology; basis for referral not described
Exclusion criteria: none reported
Sample size (patients): no. eligible: 111
Sample size (lesions): no. eligible: 130; no. included: 114 (107 for Doppler)
Participant characteristics: mean age: 55.3 (SD 18; range 6 to 92 years). Men: 47 (42%)
Lesion characteristics: for melanomas visualised on ultrasound (n = 65), thickness ranged from 0.
15 mm to 8 mm on histology
Index tests Ultrasound: high-frequency (20 MHz) and Colour Doppler (7MHz)
Test detail: AU 4 or AU 5 Idea (Esaote-Biomedica, Genova, Italy) with a 20-MHz annular probe
(axial resolution 80 µm and lateral resolution 100 µm) and 13-MHz linear electronic probe (axial
resolution 200 µm and lateral resolution 400 µm); Colour Doppler adjustments included a pulse-
repetition frequency (PRF) of 750 Hz to 1 kHz, with a 50-Hz filter and 9 to 16 images per second
Method of diagnosis: in-person diagnosis
Prior test data available: unclear whether clinical diagnosis provided to sonographer
Diagnostic threshold: HFUS - hypoechoic, homogenous and well-defined margins; HFUS plus
Doppler - hypoechoic, homogenous and well defined plus presence of intralesional vessels
Diagnosis based on: unclear whether single or multiple observers (n not reported)
Observer qualifications: not reported
Experience in practice: not described
Experience with index test: not described
Target condition and reference
standard(s)
Type of reference standard: histological diagnosis alone
Details: none provided
Disease positive: 70; disease negative: 60
Target condition (final diagnoses)
Melanoma (invasive or in situ): 65; BCC: 4; 1 neurosarcoma
’Benign’ diagnoses: 33 benign naevi, 5 seborrhoeic keratosis, 3 melanosis, 1 thrombosing capillaritis,
1 histiocytofibroma, 1 lentigo
Flow and timing Index test to reference standard interval: not described
Exclusions: 16 lesions ’unseen’ on US were excluded (5 melanoma, 1 lentigo, and 10 benign naevi)
leaving 114 lesions reported for HFUS, 107 of which underwent Doppler ultrasound
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Bessoud 2003 (Continued)
Comparative
Notes -
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Unclear
Are the included patients and
chosen study setting appropri-
ate?
Unclear
Did the study avoid including
participants with multiple le-
sions?
No
Unclear High
DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Was the test applied and inter-
preted in a clinically applicable
manner?
Yes
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
Yes
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Bessoud 2003 (Continued)
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Unclear
Low Unclear
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Were the reference standard re-
sults
interpreted without knowledge
of the referral diagnosis?
Unclear
Expert opinion (with no his-
tological confirmation) was not
used as a reference standard
Yes
Was histology interpretation
carried out by an experienced
histopathologist or by a der-
matopathologist?
Unclear
Unclear Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
Low
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Clement 2001
Study characteristics
Patient sampling Study design: case series
Data collection: prospective
Period of data collection: November 1998 to July 1999
Country: France
Patient characteristics and set-
ting
Inclusion criteria: patients with pigmented skin tumours including melanocytic and non-
melanocytic examined before resection; clinical diagnoses described as ’hesitant’ (NB translation
from French) for more than half of lesions
Setting: secondary
Prior testing: not reported; basis for referral not described
Exclusion criteria: difficult to reach lesions (2 dermal nevus - 1 at the internal angle of the eye and
the other between the toes)
Sample size (patients): no. eligible: 160
Sample size (lesions): no. eligible: 176; no. included: 138
Participant characteristics: for full sample - mean age: 52.7 years (range 18 to 90 years). Men: 74
(46%)
Lesion characteristics: 5 melanomas not visualised on ultrasound; all had Breslow index less than
0.35 mm
Index tests Ultrasound: high-frequency (20 MHz) and Colour Doppler (7 MHz)
Test detail: used an annular linear scanning probe with theoretical spatial resolution of 80µm (axial)
and 100 µm (lateral); equipped with an ultrasonic beam variable electronics management system
to obtain an optimal focal area at penetration depths of 12.5 mm and 19 mm; for Doppler, a linear
electronic probe (frequency of ultrasound: 13 MHz, axial theoretical spatial resolution: 200 µm,
lateral: 400 µm) was used
Method of diagnosis: in-person diagnosis
Prior test data available: unclear whether clinical diagnosis provided to sonographer
Diagnostic threshold: HFUS - hypoechoic; hypoechoic and homogenous; hypoechoic and well
defined; HFUS + Doppler - hypoechoic and presence of vascularity
Diagnosis based on: unclear whether single or multiple observers (n not reported)
Observer qualifications: not reported
Experience in practice: not described
Experience with index test: not described
Target condition and reference
standard(s)
Type of reference standard: histological diagnosis alone
Details: none provided
Disease positive: 24; disease negative: 115
Target condition (final diagnoses)
Melanoma (invasive or in situ): 1; BCC: 23; 6 melanoma metastases (considered disease negative
for this review)
’Benign’ diagnoses: 61 benign naevi, 29 seborrhoeic keratosis, 11 histiocytofibroma, 7 angioma
Flow and timing Index test to reference standard interval: consecutive; each lesion scanned immediately before its
biopsy or surgical excision, or both
Exclusions: 36 lesions were not visualised on US and were excluded (including 5 melanomas in
the horizontal growth phase (Clark levels I and II, Breslow index less than 0.35 mm)) leaving 138
lesions reported for HFUS
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Clement 2001 (Continued)
Comparative
Notes -
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Unclear
Are the included patients and
chosen study setting appropri-
ate?
Yes
Did the study avoid including
participants with multiple le-
sions?
Yes
Unclear Low
DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
No
Was the test applied and inter-
preted in a clinically applicable
manner?
Yes
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
Yes
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Clement 2001 (Continued)
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Unclear
High Unclear
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Were the reference standard re-
sults
interpreted without knowledge
of the referral diagnosis?
Unclear
Expert opinion (with no his-
tological confirmation) was not
used as a reference standard
Yes
Was histology interpretation
carried out by an experienced
histopathologist or by a der-
matopathologist?
Unclear
Unclear Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
Low
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Dummer 1995
Study characteristics
Patient sampling Study design: case series
Data collection: unclear
Period of data collection: not reported
Country: Germany
Patient characteristics and set-
ting
Inclusion criteria: patients with pigmented skin lesions referred from the outpatient clinic to the
Department of Dermatology
Setting: secondary
Prior testing: all patients underwent physical examination and 508 underwent dermoscopy before
HFUS; basis for referral not described
Exclusion criteria: none reported
Sample size (patients): no. eligible: not reported
Sample size (lesions): no. eligible: 792; no. included: 792
Participant characteristics: mean age: not reported. Men: not reported
Lesion characteristics: for the 108 melanomas, Breslow thickness was < 0.76 mm in 45; 0.76 mm
to 1.5 mm in 26; 1.5 mm to 4.0 mm in 24; and > 4.0 mm in 12
Index tests Ultrasound: high-frequency (20 MHz)
Test detail: DUB 20 (Taberna pro Medicum, Luneburg, Germany) at axial resolution 80 µm and
lateral resolution 200 µm. Several sonographic scans were carried out perpendicular to the previous
ones in parallel planes for each individual tumour; B-scan section corresponds to a width of 12.8
mm and a depth of 7.5 mm
Method of diagnosis: in-person diagnosis
Prior test data available: unclearwhether clinical or dermoscopy diagnosis provided to sonographer;
no data available for overall dermoscopy diagnosis
Diagnostic threshold: echo poor (hypoechoic); echo poor with no internal echoes; echo poor with
sharp basal margins; echo poor with sharp lateral margins
Diagnosis based on: unclear whether single or multiple observers (n not reported)
Observer qualifications: not reported
Experience in practice: not described
Experience with index test: not described
Target condition and reference
standard(s)
Type of reference standard: histological diagnosis alone
Details: excisional biopsy; reviewed by the dermatopathology staff at the departments of dermatol-
ogy (Universities of Wurzburg and Munich, Germany) and 78 lesions additionally reviewed by the
dermatopathology staff of the department of dermatology, University Hospital, Zurich, Switzerland
Disease positive: 173; disease negative: 619
Target condition (final diagnoses)
Melanoma (invasive or in situ): 108; BCC: 65
’Benign’ diagnoses: 307 benign naevi, 211 seborrhoeic keratosis, 47 angioma, and 54 dermatofi-
broma
Flow and timing Index test to reference standard interval: appears consecutive; patients were subjected to ELM and
ultrasound examination. After excisional biopsy, the correlationbetween clinical, ELM, sonographic,
and histologic diagnosis was established
Exclusions: no exclusions due to lack of visualisation on ultrasound
Comparative
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Dummer 1995 (Continued)
Notes -
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Unclear
Are the included patients and
chosen study setting appropri-
ate?
Unclear
Did the study avoid including
participants with multiple le-
sions?
Unclear
Unclear Unclear
DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
No
Was the test applied and inter-
preted in a clinically applicable
manner?
Yes
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
Yes
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Unclear
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Dummer 1995 (Continued)
High Unclear
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Were the reference standard re-
sults
interpreted without knowledge
of the referral diagnosis?
Unclear
Expert opinion (with no his-
tological confirmation) was not
used as a reference standard
Yes
Was histology interpretation
carried out by an experienced
histopathologist or by a der-
matopathologist?
Yes
Unclear Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Unclear
Unclear
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Harland 2000
Study characteristics
Patient sampling Study design: case control (only specific diagnoses included)
Data collection: unclear
Period of data collection: not reported
Country: UK
Patient characteristics and set-
ting
Inclusion criteria: patients with pigmented lesions with specific presumptive clinical diagnoses
(seborrhoeic keratosis, benign naevi or cutaneous malignant melanoma) recruited from a pigmented
lesion clinic; the referring general practitioner had considered the diagnosis of melanoma for each
lesion
Setting: specialist clinic
Prior testing: clinical diagnosis made at PLC
Exclusion criteria: lesions with macroscopic ulceration
Sample size (patients): no. eligible: not reported
Sample size (lesions): no. eligible: not reported; no. included: 69
Participant characteristics: mean age: not reported. Men: not reported
Lesion characteristics: none reported
Index tests Ultrasound: high-frequency (20 MHz)
Test detail: Dermascan-CTM 20-MHz B-scanner (Cortex Technology, ApS, Hadsund, Denmark);
axial resolution of 50 µm and a lateral resolution of 300 µm; in vivo slice 22’4 mmwidth, 13’4 mm
depth (6’7 mm with zoom factor 2) and 200 µm thickness. Scanner described as “US prototype
with a large unwieldy scanner head, such that certain sites, such as the inner canthus, are inaccessible
to examination. However, the aim of this pilot study was not to evaluate practicality of clinical use.
”
Method of diagnosis: in-person diagnosis
Prior test data available: unclear whether clinical diagnosis provided to sonographer
Diagnostic threshold: DER - dermal echogenicity ratio < 3 set to ensure sensitivity of 100% for
melanoma; EEL - absence of entry echo line (documented as either equivalent to perilesional skin
(non-enhanced) or as broadened); DER < 3 or absence of EEL
Diagnosis based on: unclear whether single or multiple observers (n not reported)
Observer qualifications: not reported
Experience in practice: not described
Experience with index test: not described
Target condition and reference
standard(s)
Type of reference standard: histological diagnosis alone
Details: histological evaluation was performed without knowledge of the ultrasound findings. His-
tological sections of tumours were prepared in the same plane as the B-scans, both being centred
upon the transverse reference line
Target condition (final diagnoses)
Melanoma (invasive): 19. Melanoma in situ: 6. BCC: 0
’Benign’ diagnoses: 15 benign naevi, 29 seborrhoeic keratosis
Flow and timing Index test to reference standard interval: not described
Exclusions: no exclusions due to lack of visualisation on ultrasound
Comparative
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Harland 2000 (Continued)
Notes -
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
Was a case-control design
avoided?
No
Did the study avoid inappropri-
ate exclusions?
No
Are the included patients and
chosen study setting appropri-
ate?
No
Did the study avoid including
participants with multiple le-
sions?
Unclear
High High
DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
No
Was the test applied and inter-
preted in a clinically applicable
manner?
No
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
Yes
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Unclear
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Harland 2000 (Continued)
High High
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the referral diagnosis?
Unclear
Expert opinion (with no his-
tological confirmation) was not
used as a reference standard
Yes
Was histology interpretation
carried out by an experienced
histopathologist or by a der-
matopathologist?
Unclear
Low Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
Unclear
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Lassau 1997
Study characteristics
Patient sampling Study design: case series
Data collection: prospective
Period of data collection: not reported
Country: France
Patient characteristics and set-
ting
Inclusion criteria: patients with skin lesions clinically suspected of being either melanoma or BCC
and scheduled for resection; includes only very specific lesion groups (MM, BCC, and benign naevi)
Setting: secondary
Prior testing: clinical diagnosis; basis for referral for US not described
Exclusion criteria: none reported
Sample size (patients): no. eligible: 70
Sample size (lesions): no. included: 70
Participant characteristics: mean age: not reported. Men: not reported
Lesion characteristics: melanoma thickness on histology ranged from 0.25 mm to 6 mm (n = 19)
Index tests Ultrasound: high-frequency (20 MHz); Colour Doppler (7 MHz)
Test detail: Esaote-Biomedica AU4 Idea (Genoa, Italy). HFUS - 20-MHz annular probe with an
axial resolution of 20 µm and a lateral resolution of 100 µm; Doppler - a 13-MHz linear probe with
an axial resolution of 200 µm and a lateral resolution of 400 µm for performing pulsed and Colour
Doppler US. Theoretical depth explored was 16 mm (HFUS) and 40 mm (linear/Doppler)
Method of diagnosis: in-person diagnosis
Prior test data available: unclear whether clinical diagnosis provided to sonographer
Diagnostic threshold: HFUS - hypoechoic with a homogeneous echostructure and well-defined
lower and lateral margins; HFUS plus Doppler: hypoechoic with a homogeneous echostructure and
well-defined lower and lateral margins OR presence of intratumoral vessels on Doppler
Diagnosis based on: unclear whether single or multiple observers (n not reported)
Observer qualifications: not reported
Experience in practice: not described
Experience with index test: not described
Target condition and reference
standard(s)
Type of reference standard: histological diagnosis alone
Details: none reported
Target condition (final diagnoses)
Melanoma (invasive or in situ): 19; BCC: 31; plus 1 neurosarcoma
’Benign’ diagnoses: 12 benign naevi, seborrhoeic keratosis
Flow and timing Index test to reference standard interval: “After surgical resection, tumors were analyzed histolog-
ically”
Exclusions: 6/38 clinically suspected MEL not visualised on HFUS (including 3 melanomas); plus
1/32 suspected BCC lesions were not visualised onUS andwere excluded leaving 63 lesions reported
for HFUS
Comparative
Notes -
Methodological quality
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Lassau 1997 (Continued)
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Unclear
Are the included patients and
chosen study setting appropri-
ate?
No
Did the study avoid including
participants with multiple le-
sions?
Yes
Unclear High
DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
No
Was the test applied and inter-
preted in a clinically applicable
manner?
Yes
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
Yes
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Unclear
High Unclear
DOMAIN 3: Reference Standard
53High-frequency ultrasound for diagnosing skin cancer in adults (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Lassau 1997 (Continued)
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Were the reference standard re-
sults
interpreted without knowledge
of the referral diagnosis?
Unclear
Expert opinion (with no his-
tological confirmation) was not
used as a reference standard
Yes
Was histology interpretation
carried out by an experienced
histopathologist or by a der-
matopathologist?
Unclear
Unclear Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
Low
Rallan 2007
Study characteristics
Patient sampling Study design: case control (only selected diagnoses included)
Data collection: unclear
Period of data collection: not reported
Country: UK
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Rallan 2007 (Continued)
Patient characteristics and set-
ting
Inclusion criteria: patients referred to a skin cancer clinic with a suspicion of melanoma and with
a subsequent clinical diagnosis of SK, benign nevus, or suspicion of melanoma
Setting: specialist clinic
Prior testing: clinical diagnosis by a dermatologist; basis for referral for US not described
Exclusion criteria: head/neck excluded; > 20 mm excluded
Sample size (patients): no. eligible: 87
Sample size (lesions): no. included: 87
Participant characteristics: mean age: not reported (range 21 to 67 years). Men: 24; 28%
Lesion characteristics: mean Breslow thickness for invasive melanomas: 0.97 ± 0.29 mm, range 0.
25 mm to 2.0 mm
Index tests Ultrasound: high-frequency (20 MHz) with reflex transmission imaging (RTI)
Test detail: Dermascan Cv3 Cortex ApS (Denmark); 3 types of images generated - a reflex transmis-
sion image (RTI) predominantly influenced by ultrasonic attenuation in the focal plane, a lesional
backscatter image (LBI) based on an integration zone through the lesion body and an entry echo
image (EEI) based on an integration zone through the skin surface. Quote: “RTI parameters refer
to lesion attenuation properties, LBI and EEI parameters depict intralesional sound reflection and
surface sound reflectance characteristics, respectively”. Referenced to Rallan 2006; however, rela-
tively experimental in nature.
Method of diagnosis: in-person diagnosis
Prior test data available: unclear whether clinical diagnosis provided to sonographer
Diagnostic threshold: based on presence of statistically significant characteristics related to contrast
and relative heterogeneity of each type of image (these were identified from comparison of mean
values between MM vs SK and MM vs BN). Three significant characteristics were identified - RTI
contrast, LBI relative heterogeneity, and EEI relative heterogeneity
Diagnosis based on: unclear whether single or multiple observers (n not reported)
Observer qualifications: not reported
Experience in practice: not described
Experience with index test: not described
Target condition and reference
standard(s)
Type of reference standard: histological diagnosis alone
Details: lesions were “removed under local anaesthetic following data acquisition. Histological di-
agnosis was then used to classify the lesion in one of three groups, MM, SK, or other benign-pig-
mented lesion. In cases of histological atypia or dyplasia, suggesting but not confirming melanoma,
the lesion was classed in accordance with the clinical management protocol (usually as melanoma).
”
Target condition (final diagnoses)
Melanoma (invasive): 14; melanoma in situ: 11; BCC: 0.
’Benign’ diagnoses: 38 benign naevi, 24 seborrhoeic keratosis
Flow and timing Index test to reference standard interval: consecutive
Exclusions: no lesions reported that were not visualised on US
Comparative
Notes -
Methodological quality
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Rallan 2007 (Continued)
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
Was a case-control design
avoided?
No
Did the study avoid inappropri-
ate exclusions?
No
Are the included patients and
chosen study setting appropri-
ate?
No
Did the study avoid including
participants with multiple le-
sions?
Yes
High High
DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
No
Was the test applied and inter-
preted in a clinically applicable
manner?
No
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
Yes
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Unclear
High High
DOMAIN 3: Reference Standard
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Rallan 2007 (Continued)
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Were the reference standard re-
sults
interpreted without knowledge
of the referral diagnosis?
Unclear
Expert opinion (with no his-
tological confirmation) was not
used as a reference standard
Yes
Was histology interpretation
carried out by an experienced
histopathologist or by a der-
matopathologist?
Unclear
Unclear Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
Low
BCC: basal cell carcinoma; BN: benign naevi; DER: dermal echogenicity ratio; EEI: entry echo image; EEL: entry echo line; ELM:
epiluminescence microscopy; HFUS: high-frequency ultrasound; Hz: hertz; LBI: lesional backscatter image; MEL: melanoma
(invasive and in situ);; MM: malignant melanoma; PLC: pigmented lesion clinic; PRF: pulse-repetition frequency; RTI: reflex
transmission image; SK: seborrhoeic keratosis; US: ultrasound.
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Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Akata 1998 Inappropriate index test; Doppler US
Bens 2015 Assesses individual lesion characteristics only; assesses echogenicity alone and we required at least two
HFUS features to be examined in combination
Bezugly 2015 Not a primary study
Bobadilla 2008 Inappropriate study population; only BCC lesions included
Cardenas 2009 Inappropriate index test; 17 MHz frequency
Delfino 2013 Inappropriate index test; 17-MHz ultrasound probe
Evans 2014 Not a primary study
Fornage 1993 Inappropriate reference standard; maximum of 41% of benign group had adequate reference standard
(if assume all malignant had histology). From paper - pathologic diagnosis obtained for 109 lesions
(54%) through shave, punch, or excisional biopsy; in the absence of pathologic analysis, the diagnosis
was based on the dermatologist’s assessment
Giovagnorio 2003 Inappropriate target condition; detection of metastases
Gropper 1993 Not a primary study; review
Harland 1993 Small sample size; 3 BCC; 1 SCC
Hernandez 2014 Not a primary study; comment paper
Hughes 1987 Inappropriate target condition; no breakdown of 17 malignant lesions undergoing Doppler
Inappropriate index test; HFUS reported for thickness only; Doppler flow ± also reported
Hunger 2012 Inappropriate index test; high-definition laser Doppler
Jambusaria-Pahlajani 2009 Inappropriate study population; only biopsy confirmed BCC or SCC
Inappropriate target condition; detection of surgical margin
Karaman 2001 Inappropriate index test; power Doppler
Krahn 1998 Inappropriate target condition; exclude high-frequency ultrasound data - only reports accurate detection
of lesion thickness
Maj 2015 No 2 × 2 data; paper refers to Table I which contains ’detailed data’ but there is no Table I in the paper
Authors contacted December 2016 and May 2017
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(Continued)
Marques 2002 Inappropriate index test; 10 MHz ultrasound - not high frequency
Meyer 2014 Inappropriate target condition; identification of lesion thickness only
Ozkol 2006 Inappropriate target condition;D+group includes 1dermatofibroma and1Bowen’s; cannot disaggregate
Inappropriate index test; Colour Doppler
Petik 2013 Inappropriate index test; Colour Doppler plus power Doppler if vascularity not clearly identified
Rallan 2006 Derivation study; high-resolution ultrasound with reflex transmission imaging (RTI); also combined
with white light clinical (WLC) photography. No separate independent test set result is given; also
’white light’ data is CAD based
Ravi 2000 Inappropriate index test; Colour Doppler
Samimi 2010 Inappropriate study population; blue naevus or melanoma metastasis
Inappropriate target condition; melanoma metastasis
Schroder 1999 Inappropriate index test; not high frequency (10 MHz US)
Schröder 2001 Inappropriate index test; not HFUS
Scotto 2015 Inappropriate index test; US (5-17 MHz) and Doppler
Song 2014 Inappropriate index test; not HFUS (7-15 MHz)
Srivastava 1986 Inappropriate index test; Doppler US
Stucker 2002 Inappropriate index test; laser Doppler; assessment of blood flow
Stücker 1999 Inappropriate index test; laser Doppler US
No 2 × 2 data; comparing mean tumour perfusion values between groups only
Wortsman 2010 Inappropriate target condition; can estimate sensitivity for detection of malignancy but cannot estimate
specificity for benign lesions assessed to either rule in or rule out malignancy
Inappropriate index test; up to 15 MHz ultrasound
No 2 × 2 data; could get 2 × 2 from Table 1 but disease negative includes huge range of diagnoses that
are not relevant to our review
Wortsman 2013 Not a primary study
BCC: basal cell carcinoma; CAD: computer-assisted diagnosis; HFUS: high-frequency ultrasound; SCC: squamous cell carcinoma;
US: ultrasound; VI: visual inspection.
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Characteristics of studies awaiting classification [ordered by study ID]
Nitsche 1992
Study characteristics
Patient sampling -
Patient characteristics and set-
ting
-
Index tests -
Target condition and reference
standard(s)
-
Flow and timing -
Comparative -
Notes British Library unable to supply copy of the paper
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D A T A
Presented below are all the data for all of the tests entered into the review.
Tests. Data tables by test
Test
No. of
studies
No. of
participants
1 Melanoma - hypoechoic 1 792
2 Melanoma - hypoechoic and
homogenous
1 792
3 Melanoma - hypoechoic and
sharp basal margins
1 792
4 Melanoma - hypoechoic and
sharp lateral margins
1 792
5 Melanoma - hypoechoic,
homogenous and well defined
2 177
6 Melanoma (melanoma vs
benign naevi) - hypoechoic,
homogenous and well defined
1 32
7 Melanoma (melanoma vs
seborrhoeic keratosis) - dermal
echogenicity ratio < 3
1 54
8 Melanoma (melanoma vs
seborrhoeic keratosis) - absence
of entry echo line
1 54
9 Melanoma (melanoma vs
seborrhoeic keratosis) - dermal
echogenicity ratio < 3 OR
absence of entry echo line
1 54
10 Melanoma (melanoma vs
seborrhoeic keratosis or benign
naevi) - absence of entry echo
line
1 69
11 Melanoma - reflex transmission
image contrast/lesional
backscatter image relative.
Heterogeneity/entry echo
image relative heterogeneity
1 87
12 Melanoma - HFUS positive
OR Doppler positive
1 63
13 Melanoma (melanoma vs
benign naevi) - HFUS positive
OR Doppler positive
1 32
14 Melanoma - HFUS positive
AND Doppler positive
2 170
15 BCC - hypoechoic 2 930
16 BCC - hypoechoic and
homogenous
2 930
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17 BCC - hypoechoic and well
defined
1 138
18 BCC - hypoechoic and sharp
basal margins
1 792
19 BCC - hypoechoic and sharp
lateral margins
1 792
20 BCC - hypoechoic,
homogenous and well defined
1 63
21 BCC - hypoechoic,
heterogenous with irregular
margins
1 63
22 BCC - HFUS positive AND
Doppler positive
1 138
Test 1. Melanoma - hypoechoic.
Review: High-frequency ultrasound for diagnosing skin cancer in adults
Test: 1 Melanoma - hypoechoic
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Dummer 1995 108 619 0 65 1.00 [ 0.97, 1.00 ] 0.10 [ 0.07, 0.12 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 2. Melanoma - hypoechoic and homogenous.
Review: High-frequency ultrasound for diagnosing skin cancer in adults
Test: 2 Melanoma - hypoechoic and homogenous
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Dummer 1995 90 248 18 436 0.83 [ 0.75, 0.90 ] 0.64 [ 0.60, 0.67 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 3. Melanoma - hypoechoic and sharp basal margins.
Review: High-frequency ultrasound for diagnosing skin cancer in adults
Test: 3 Melanoma - hypoechoic and sharp basal margins
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Dummer 1995 94 491 14 193 0.87 [ 0.79, 0.93 ] 0.28 [ 0.25, 0.32 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 4. Melanoma - hypoechoic and sharp lateral margins.
Review: High-frequency ultrasound for diagnosing skin cancer in adults
Test: 4 Melanoma - hypoechoic and sharp lateral margins
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Dummer 1995 98 532 10 152 0.91 [ 0.84, 0.95 ] 0.22 [ 0.19, 0.26 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 5. Melanoma - hypoechoic, homogenous and well defined.
Review: High-frequency ultrasound for diagnosing skin cancer in adults
Test: 5 Melanoma - hypoechoic, homogenous and well defined
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Bessoud 2003 65 33 0 16 1.00 [ 0.94, 1.00 ] 0.33 [ 0.20, 0.48 ]
Lassau 1997 19 12 0 32 1.00 [ 0.82, 1.00 ] 0.73 [ 0.57, 0.85 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 6. Melanoma (melanoma vs benign naevi) - hypoechoic, homogenous and well defined.
Review: High-frequency ultrasound for diagnosing skin cancer in adults
Test: 6 Melanoma (melanoma vs benign naevi) - hypoechoic, homogenous and well defined
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Lassau 1997 19 12 0 1 1.00 [ 0.82, 1.00 ] 0.08 [ 0.00, 0.36 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 7. Melanoma (melanoma vs seborrhoeic keratosis) - dermal echogenicity ratio < 3.
Review: High-frequency ultrasound for diagnosing skin cancer in adults
Test: 7 Melanoma (melanoma vs seborrhoeic keratosis) - dermal echogenicity ratio < 3
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Harland 2000 25 6 0 23 1.00 [ 0.86, 1.00 ] 0.79 [ 0.60, 0.92 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 8. Melanoma (melanoma vs seborrhoeic keratosis) - absence of entry echo line.
Review: High-frequency ultrasound for diagnosing skin cancer in adults
Test: 8 Melanoma (melanoma vs seborrhoeic keratosis) - absence of entry echo line
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Harland 2000 24 3 1 26 0.96 [ 0.80, 1.00 ] 0.90 [ 0.73, 0.98 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 9. Melanoma (melanoma vs seborrhoeic keratosis) - dermal echogenicity ratio < 3 OR absence of
entry echo line.
Review: High-frequency ultrasound for diagnosing skin cancer in adults
Test: 9 Melanoma (melanoma vs seborrhoeic keratosis) - dermal echogenicity ratio < 3 OR absence of entry echo line
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Harland 2000 25 2 0 27 1.00 [ 0.86, 1.00 ] 0.93 [ 0.77, 0.99 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 10. Melanoma (melanoma vs seborrhoeic keratosis or benign naevi) - absence of entry echo line.
Review: High-frequency ultrasound for diagnosing skin cancer in adults
Test: 10 Melanoma (melanoma vs seborrhoeic keratosis or benign naevi) - absence of entry echo line
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Harland 2000 24 12 1 32 0.96 [ 0.80, 1.00 ] 0.73 [ 0.57, 0.85 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 11. Melanoma - reflex transmission image contrast/lesional backscatter image relative.
Heterogeneity/entry echo image relative heterogeneity.
Review: High-frequency ultrasound for diagnosing skin cancer in adults
Test: 11 Melanoma - reflex transmission image contrast/lesional backscatter image relative. Heterogeneity/entry echo image relative heterogeneity
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Rallan 2007 25 22 0 40 1.00 [ 0.86, 1.00 ] 0.65 [ 0.51, 0.76 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 12. Melanoma - HFUS positive OR Doppler positive.
Review: High-frequency ultrasound for diagnosing skin cancer in adults
Test: 12 Melanoma - HFUS positive OR Doppler positive
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Lassau 1997 19 12 0 32 1.00 [ 0.82, 1.00 ] 0.73 [ 0.57, 0.85 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 13. Melanoma (melanoma vs benign naevi) - HFUS positive OR Doppler positive.
Review: High-frequency ultrasound for diagnosing skin cancer in adults
Test: 13 Melanoma (melanoma vs benign naevi) - HFUS positive OR Doppler positive
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Lassau 1997 19 12 0 1 1.00 [ 0.82, 1.00 ] 0.08 [ 0.00, 0.36 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 14. Melanoma - HFUS positive AND Doppler positive.
Review: High-frequency ultrasound for diagnosing skin cancer in adults
Test: 14 Melanoma - HFUS positive AND Doppler positive
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Bessoud 2003 21 0 41 45 0.34 [ 0.22, 0.47 ] 1.00 [ 0.92, 1.00 ]
Lassau 1997 3 0 16 44 0.16 [ 0.03, 0.40 ] 1.00 [ 0.92, 1.00 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 15. BCC - hypoechoic.
Review: High-frequency ultrasound for diagnosing skin cancer in adults
Test: 15 BCC - hypoechoic
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Clement 2001 23 110 0 5 1.00 [ 0.85, 1.00 ] 0.04 [ 0.01, 0.10 ]
Dummer 1995 65 727 0 0 1.00 [ 0.94, 1.00 ] 0.0 [ 0.0, 0.01 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 16. BCC - hypoechoic and homogenous.
Review: High-frequency ultrasound for diagnosing skin cancer in adults
Test: 16 BCC - hypoechoic and homogenous
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Clement 2001 21 99 2 16 0.91 [ 0.72, 0.99 ] 0.14 [ 0.08, 0.22 ]
Dummer 1995 5 338 60 389 0.08 [ 0.03, 0.17 ] 0.54 [ 0.50, 0.57 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 17. BCC - hypoechoic and well defined.
Review: High-frequency ultrasound for diagnosing skin cancer in adults
Test: 17 BCC - hypoechoic and well defined
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Clement 2001 19 78 4 37 0.83 [ 0.61, 0.95 ] 0.32 [ 0.24, 0.42 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 18. BCC - hypoechoic and sharp basal margins.
Review: High-frequency ultrasound for diagnosing skin cancer in adults
Test: 18 BCC - hypoechoic and sharp basal margins
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Dummer 1995 56 585 9 142 0.86 [ 0.75, 0.93 ] 0.20 [ 0.17, 0.23 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 19. BCC - hypoechoic and sharp lateral margins.
Review: High-frequency ultrasound for diagnosing skin cancer in adults
Test: 19 BCC - hypoechoic and sharp lateral margins
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Dummer 1995 27 630 38 97 0.42 [ 0.29, 0.54 ] 0.13 [ 0.11, 0.16 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 20. BCC - hypoechoic, homogenous and well defined.
Review: High-frequency ultrasound for diagnosing skin cancer in adults
Test: 20 BCC - hypoechoic, homogenous and well defined
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Lassau 1997 0 31 31 1 0.0 [ 0.0, 0.11 ] 0.03 [ 0.00, 0.16 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 21. BCC - hypoechoic, heterogenous with irregular margins.
Review: High-frequency ultrasound for diagnosing skin cancer in adults
Test: 21 BCC - hypoechoic, heterogenous with irregular margins
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Lassau 1997 31 1 0 31 1.00 [ 0.89, 1.00 ] 0.97 [ 0.84, 1.00 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 22. BCC - HFUS positive AND Doppler positive.
Review: High-frequency ultrasound for diagnosing skin cancer in adults
Test: 22 BCC - HFUS positive AND Doppler positive
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Clement 2001 0 13 23 102 0.0 [ 0.0, 0.15 ] 0.89 [ 0.81, 0.94 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
A P P E N D I C E S
Appendix 1. Current content and structure of the Programme Grant
LIST OF REVIEWS Number of studies
Diagnosis of melanoma
1 Visual inspection 49
2 Dermoscopy +/- visual inspection 104
3 Teledermatology 22
4 Smartphone applications 2
5a Computer-assisted diagnosis - dermoscopy-based techniques 42
5b Computer-assisted diagnosis - spectroscopy-based techniques Review amalgamated into 5a
6 Reflectance confocal microscopy 18
7 High-frequency ultrasound 5
Diagnosis of keratinocyte skin cancer (BCC and cSCC)
8 Visual inspection +/- Dermoscopy 24
5c Computer-assisted diagnosis - dermoscopy-based techniques Review amalgamated into 5a
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(Continued)
5d Computer-assisted diagnosis - spectroscopy-based techniques Review amalgamated into 5a
9 Optical coherence tomography 5
10 Reflectance confocal microscopy 10
11 Exfoliative cytology 9
Staging of melanoma
12 Imaging tests (ultrasound, CT, MRI, PET-CT) 38
13 Sentinel lymph node biopsy 160
Staging of cSCC
Imaging tests review Review dropped; only one study identified
13 Sentinel lymph node biopsy Review amalgamated into 13 above (n = 15 studies)
Appendix 2. Glossary of terms
Term Definition
Atypical intraepidermal melanocytic variant Unusual area of darker pigmentation contained within the epidermis that may
progress to an invasive melanoma; includes melanoma in situ and lentigo maligna
Atypical naevi Unusual looking but non-cancerous mole or area of darker pigmentation of the
skin
BRAF V600 mutation BRAF is a human gene that makes a protein called B-Raf which is involved in the
control of cell growth. BRAF mutations (damaged DNA) occur in around 40%
of melanomas, which can then be treated with particular drugs
BRAF inhibitors Therapeutic agents that inhibit the serine-threonine protein kinase BRAFmutated
metastatic melanoma
Breslow thickness A scale for measuring the thickness of melanomas by the pathologist using a
microscope, measured in mm from the top layer of skin to the bottom of the
tumour
Congenital naevi A type of mole found on infants at birth
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(Continued)
Dermoscopy Whereby a handheld microscope is used to allow more detailed, magnified exam-
ination of the skin compared to examination by the naked eye alone
False negative An individual who is truly positive for a disease, but whom a diagnostic test
classifies as disease-free
False positive An individual who is truly disease-free, but whom a diagnostic test classifies as
having the disease
Histopathology/histology The study of tissue, usually obtained by biopsy or excision, for example under a
microscope
Incidence The number of new cases of a disease in a given time period
Index test A diagnostic test under evaluation in a primary study
Lentigo maligna Unusual area of darker pigmentation contained within the epidermis which in-
cludes malignant cells but with no invasive growth. May progress to an invasive
melanoma
Lymph node Lymph nodes filter the lymphatic fluid (clear fluid containing white blood cells)
that travels around the body to help fight disease; they are located throughout the
body often in clusters (nodal basins)
Melanocytic naevus An area of skin with darker pigmentation (or melanocytes) also referred to as
’moles’
Meta-analysis A form of statistical analysis used to synthesise results from a collection of indi-
vidual studies
Metastases/metastatic disease Spread of cancer away from the primary site to somewhere else through the blood-
stream or the lymphatic system
Micrometastases Micrometastases are metastases so small that they can only be seen under a mi-
croscope
Mitotic rate Microscopic evaluation of number of cells actively dividing in a tumour
Morbidity Detrimental effects on health
Mortality Either the condition of being subject to death; or the death rate, which reflects
the number of deaths per unit of population in relation to any specific region, age
group, disease, treatment or other classification, usually expressed as deaths per
100, 1000, 10,000 or 100,000 people
Multidisciplinary team A team with members from different healthcare professions and specialties (e.g.
urology, oncology, pathology, radiology, and nursing). Cancer care in theNational
Health Service (NHS) uses this system to ensure that all relevant health profes-
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(Continued)
sionals are engaged to discuss the best possible care for that patient
Prevalence The proportion of a population found to have a condition
Prognostic factors/indicators Specific characteristics of a cancer or the person who has it which might affect the
patient’s prognosis
Receiver operating characteristic (ROC) plot A plot of the sensitivity and 1minus the specificity of a test at the different possible
thresholds for test positivity; represents the diagnostic capability of a test with a
range of binary test results
Receiver operating characteristic (ROC) analysis The analysis of a ROCplot of a test to select an optimal threshold for test positivity
Recurrence Recurrence is when new cancer cells are detected following treatment. This can
occur either at the site of the original tumour or at other sites in the body
Reference standard A test or combination of tests used to establish the final or ’true’ diagnosis of a
patient in an evaluation of a diagnostic test
Reflectance confocal microscopy (RCM) A microscopic technique using infrared light (either in a handheld device or a
static unit) that can create images of the deeper layers of the skin
Sensitivity In this context the term is used to mean the proportion of individuals with a
disease who have that disease correctly identified by the study test
Specificity The proportion of individuals without the disease of interest (in this case with
benign skin lesions) who have that absence of disease correctly identified by the
study test
Staging Clinical description of the size and spread of a patient’s tumour, fitting into inter-
nationally agreed categories
Subclinical (disease) Disease that is usually asymptomatic and not easily observable, e.g. by clinical or
physical examination
Systemic treatment Treatment, usually given by mouth or by injection, that reaches and affects cancer
cells throughout the body rather than targeting one specific area
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Appendix 3. Table of acronyms and abbreviations used
Acronym Definition
µm micrometre
B-mode brightness mode
BCC basal cell carcinoma
BN benign naevi
BPC between-person comparison (of tests)
CAD computer-assisted diagnosis
cSCC cutaneous squamous cell carcinoma
DER dermal echogenicity ratio
EEI entry echo image
EEL entry echo line
ELM epiluminescence microscopy
GP general practitioner
HFUS high-frequency ultrasound
KHz kilohertz
LBI lesional backscatter image
MHz megahertz
mm millimetre
PCPs primary care providers
RCM reflectance confocal microscopy
RCT randomised controlled trial
RTI reflex transmission image
SCC squamous cell carcinoma
SD standard deviation
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(Continued)
US ultrasound
Appendix 4. Proposed sources of heterogeneity
i. Population characteristics
• general versus higher risk populations
• patient population: Primary /secondary / specialist unit
• lesion suspicion: general suspicion/atypical/equivocal/NR
• lesion type: any pigmented; melanocytic
• inclusion of multiple lesions per participant
• ethnicity
ii. Index test characteristics
• the nature of and definition of criteria for test positivity
• observer experience with the index test
• approaches to lesion preparation (e.g. the use of oil or antiseptic gel for dermoscopy)
iii. Reference standard characteristics
• reference standard used
• whether histology-reporting meets pathology-reporting guidelines
• use of excisional versus diagnostic biopsy
• whether two independent dermatopathologists reviewed histological diagnosis
iv. Study quality
• consecutive or random sample of participants recruited
• index test interpreted blinded to the reference standard result
• index test interpreted blinded to the result of any other index test
• presence of partial or differential verification bias (whereby only a sample of those subject to the index test are verified by the
reference test or by the same reference test with selection dependent on the index test result)
• use of an adequate reference standard
• overall risk of bias
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Appendix 5. Final search strategies
Melanoma search strategies to August 2016
Database: Ovid MEDLINE(R) 1946 to August week 3 2016
Search strategy:
1 exp melanoma/
2 exp skin cancer/
3 exp basal cell carcinoma/
4 basalioma$1.ti,ab.
5 ((basal cell or skin) adj2 (cancer$1 or carcinoma$1 or mass or masses or tumour$1 or tumor$1 or neoplasm$1 or adenoma$1 or
epithelioma$1 or lesion$1 or malignan$ or nodule$1)).ti,ab.
6 (pigmented adj2 (lesion$1 or mole$ or nevus or nevi or naevus or naevi or skin)).ti,ab.
7 (melanom$1 or nonmelanoma$1 or non-melanoma$1 or melanocyt$ or non-melanocyt$ or nonmelanocyt$ or keratinocyt$).ti,ab.
8 nmsc.ti,ab.
9 (squamous cell adj2 (cancer$1 or carcinoma$1 or mass or masses or tumor$1 or tumour$1 or neoplasm$1 or adenoma$1 or
epithelioma$1 or epithelial or lesion$1 or malignan$ or nodule$1) adj2 (skin or epiderm$ or cutaneous)).ti,ab.
10 (BCC or CSCC or NMSC).ti,ab.
11 keratinocy$.ti,ab.
12 Keratinocytes/
13 or/1-12
14 dermoscop$.ti,ab.
15 dermatoscop$.ti,ab.
16 photomicrograph$.ti,ab.
17 exp epiluminescence microscopy/
18 (epiluminescence adj2 microscop$).ti,ab.
19 (confocal adj2 microscop$).ti,ab.
20 (incident light adj2 microscop$).ti,ab.
21 (surface adj2 microscop$).ti,ab.
22 (visual adj (inspect$ or examin$)).ti,ab.
23 ((clinical or physical) adj examin$).ti,ab.
24 3 point.ti,ab.
25 three point.ti,ab.
26 pattern analys$.ti,ab.
27 ABCD$.ti,ab.
28 menzies.ti,ab.
29 7 point.ti,ab.
30 seven point.ti,ab.
31 (digital adj2 (dermoscop$ or dermatoscop$)).ti,ab.
32 artificial intelligence.ti,ab.
33 AI.ti,ab.
34 computer assisted.ti,ab.
35 computer aided.ti,ab.
36 neural network$.ti,ab.
37 exp diagnosis, computer-assisted/
38 MoleMax.ti,ab.
39 image process$.ti,ab.
40 automatic classif$.ti,ab.
41 image analysis.ti,ab.
42 SIAscop$.ti,ab.
43 Aura.ti,ab.
44 (optical adj2 scan$).ti,ab.
45 MelaFind.ti,ab.
46 SIMSYS.ti,ab.
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47 MoleMate.ti,ab.
48 SolarScan.ti,ab.
49 VivaScope.ti,ab.
50 (high adj3 ultraso$).ti,ab.
51 (canine adj2 detect$).ti,ab.
52 ((mobile or cell or cellular or smart) adj ((phone$1 adj2 app$1) or application$1)).ti,ab.
53 smartphone$.ti,ab.
54 (DermoScan or SkinVision or DermLink or SpotCheck).ti,ab.
55 Mole Detective.ti,ab.
56 Spot Check.ti,ab.
57 (mole$1 adj2 map$).ti,ab.
58 (total adj2 body).ti,ab.
59 exfoliative cytolog$.ti,ab.
60 digital analys$.ti,ab.
61 (image$1 adj3 software).ti,ab.
62 (teledermatolog$ or tele-dermatolog$ or telederm or tele-derm or teledermoscop$ or tele-dermoscop$ or teledermatoscop$ or tele-
dermatoscop$).ti,ab.
63 (optical coherence adj (technolog$ or tomog$)).ti,ab.
64 (computer adj2 diagnos$).ti,ab.
65 exp sentinel lymph node biopsy/
66 (sentinel adj2 node).ti,ab.
67 nevisense.mp. or HFUS.ti,ab.
68 electrical impedance spectroscopy.ti,ab.
69 history taking.ti,ab.
70 patient history.ti,ab.
71 (naked eye adj (exam$ or assess$)).ti,ab.
72 (skin adj exam$).ti,ab.
73 physical examination/
74 ugly duckling.mp. or UD.ti,ab.
75 ((physician$ or clinical or physical) adj (exam$ or triage or recog$)).ti,ab.
76 ABCDE.mp. or VOC.ti,ab.
77 clinical accuracy.ti,ab.
78 Family Practice/ or Physicians, Family/ or clinical competence/
79 (confocal adj2 microscop$).ti,ab.
80 diagnostic algorithm$1.ti,ab.
81 checklist$.ti,ab.
82 virtual imag$1.ti,ab.
83 volatile organic compound$1.ti,ab.
84 dog$1.ti,ab.
85 gene expression analy$.ti,ab.
86 reflex transmission imag$.ti,ab.
87 thermal imaging.ti,ab.
88 elastography.ti,ab.
89 or/14-88
90 (CT or PET).ti,ab.
91 PET-CT.ti,ab.
92 (FDG or F18 or Fluorodeoxyglucose or radiopharmaceutical$).ti,ab.
93 exp Deoxyglucose/
94 deoxy-glucose.ti,ab.
95 deoxyglucose.ti,ab.
96 CATSCAN.ti,ab.
97 exp Tomography, Emission-Computed/
98 exp Tomography, X-ray computed/
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99 positron emission tomograph$.ti,ab.
100 exp magnetic resonance imaging/
101 (MRI or fMRI or NMRI or scintigraph$).ti,ab.
102 exp echography/
103 Doppler echography.ti,ab.
104 sonograph$.ti,ab.
105 ultraso$.ti,ab.
106 doppler.ti,ab.
107 magnetic resonance imag$.ti,ab.
108 or/90-107
109 (stage$ or staging or metasta$ or recurrence or sensitivity or specificity or false negative$ or thickness$).ti,ab.
110 “Sensitivity and Specificity”/
111 exp cancer staging/
112 or/109-111
113 108 and 112
114 89 or 113
115 13 and 114
Database: Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations 29 August 2016
Search strategy:
1 basalioma$1.ti,ab.
2 ((basal cell or skin) adj2 (cancer$1 or carcinoma$1 or mass or masses or tumour$1 or tumor$1 or neoplasm$1 or adenoma$1 or
epithelioma$1 or lesion$1 or malignan$ or nodule$1)).ti,ab.
3 (pigmented adj2 (lesion$1 or mole$ or nevus or nevi or naevus or naevi or skin)).ti,ab.
4 (melanom$1 or nonmelanoma$1 or non-melanoma$1 or melanocyt$ or non-melanocyt$ or nonmelanocyt$ or keratinocyt$).ti,ab.
5 nmsc.ti,ab.
6 (squamous cell adj2 (cancer$1 or carcinoma$1 or mass or masses or tumor$1 or tumour$1 or neoplasm$1 or adenoma$1 or
epithelioma$1 or epithelial or lesion$1 or malignan$ or nodule$1) adj2 (skin or epiderm$ or cutaneous)).ti,ab.
7 (BCC or CSCC or NMSC).ti,ab.
8 keratinocy$.ti,ab.
9 or/1-8
10 dermoscop$.ti,ab.
11 dermatoscop$.ti,ab.
12 photomicrograph$.ti,ab.
13 (epiluminescence adj2 microscop$).ti,ab.
14 (confocal adj2 microscop$).ti,ab.
15 (incident light adj2 microscop$).ti,ab.
16 (surface adj2 microscop$).ti,ab.
17 (visual adj (inspect$ or examin$)).ti,ab.
18 ((clinical or physical) adj examin$).ti,ab.
19 3 point.ti,ab.
20 three point.ti,ab.
21 pattern analys$.ti,ab.
22 ABCD$.ti,ab.
23 menzies.ti,ab.
24 7 point.ti,ab.
25 seven point.ti,ab.
26 (digital adj2 (dermoscop$ or dermatoscop$)).ti,ab.
27 artificial intelligence.ti,ab.
28 AI.ti,ab.
29 computer assisted.ti,ab.
30 computer aided.ti,ab.
31 neural network$.ti,ab.
32 MoleMax.ti,ab.
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33 image process$.ti,ab.
34 automatic classif$.ti,ab.
35 image analysis.ti,ab.
36 SIAscop$.ti,ab.
37 Aura.ti,ab.
38 (optical adj2 scan$).ti,ab.
39 MelaFind.ti,ab.
40 SIMSYS.ti,ab.
41 MoleMate.ti,ab.
42 SolarScan.ti,ab.
43 VivaScope.ti,ab.
44 (high adj3 ultraso$).ti,ab.
45 (canine adj2 detect$).ti,ab.
46 ((mobile or cell or cellular or smart) adj ((phone$1 adj2 app$1) or application$1)).ti,ab.
47 smartphone$.ti,ab.
48 (DermoScan or SkinVision or DermLink or SpotCheck).ti,ab.
49 Mole Detective.ti,ab.
50 Spot Check.ti,ab.
51 (mole$1 adj2 map$).ti,ab.
52 (total adj2 body).ti,ab.
53 exfoliative cytolog$.ti,ab.
54 digital analys$.ti,ab.
55 (image$1 adj3 software).ti,ab.
56 (teledermatolog$ or tele-dermatolog$ or telederm or tele-derm or teledermoscop$ or tele-dermoscop$ or teledermatoscop$ or tele-
dermatoscop$).ti,ab.
57 (optical coherence adj (technolog$ or tomog$)).ti,ab.
58 (computer adj2 diagnos$).ti,ab.
59 (sentinel adj2 node).ti,ab.
60 nevisense.mp. or HFUS.ti,ab.
61 electrical impedance spectroscopy.ti,ab.
62 history taking.ti,ab.
63 patient history.ti,ab.
64 (naked eye adj (exam$ or assess$)).ti,ab.
65 (skin adj exam$).ti,ab.
66 ugly duckling.mp. or UD.ti,ab.
67 ((physician$ or clinical or physical) adj (exam$ or triage or recog$)).ti,ab.
68 ABCDE.mp. or VOC.ti,ab.
69 clinical accuracy.ti,ab.
70 (Family adj (Practice or Physicians)).ti,ab.
71 (confocal adj2 microscop$).ti,ab.
72 clinical competence.ti,ab.
73 diagnostic algorithm$1.ti,ab.
74 checklist$.ti,ab.
75 virtual imag$1.ti,ab.
76 volatile organic compound$1.ti,ab.
77 dog$1.ti,ab.
78 gene expression analy$.ti,ab.
79 reflex transmission imag$.ti,ab.
80 thermal imaging.ti,ab.
81 elastography.ti,ab.
82 or/10-81
83 (CT or PET).ti,ab.
84 PET-CT.ti,ab.
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85 (FDG or F18 or Fluorodeoxyglucose or radiopharmaceutical$).ti,ab.
86 deoxy-glucose.ti,ab.
87 deoxyglucose.ti,ab.
88 CATSCAN.ti,ab.
89 positron emission tomograph$.ti,ab.
90 (MRI or fMRI or NMRI or scintigraph$).ti,ab.
91 Doppler echography.ti,ab.
92 sonograph$.ti,ab.
93 ultraso$.ti,ab.
94 doppler.ti,ab.
95 magnetic resonance imag$.ti,ab.
96 or/83-95
97 (stage$ or staging or metasta$ or recurrence or sensitivity or specificity or false negative$ or thickness$).ti,ab.
98 96 and 97
99 82 or 98
100 9 and 99
Database: Embase 1974 to 29 August 2016
Search strategy:
1 *melanoma/
2 *skin cancer/
3 *basal cell carcinoma/
4 basalioma$.ti,ab.
5 ((basal cell or skin) adj2 (cancer$1 or carcinoma$1 or mass or masses or tumour$1 or tumor$1 or neoplasm$ or adenoma$ or
epithelioma$ or lesion$ or malignan$ or nodule$)).ti,ab.
6 (pigmented adj2 (lesion$1 or mole$ or nevus or nevi or naevus or naevi or skin)).ti,ab.
7 (melanom$1 or nonmelanoma$1 or non-melanoma$1 or melanocyt$ or non-melanocyt$ or nonmelanocyt$ or keratinocyt$).ti,ab.
8 nmsc.ti,ab.
9 (squamous cell adj2 (cancer$1 or carcinoma$1 or mass or tumor$1 or tumour$1 or neoplasm$1 or adenoma$1 or epithelioma$1 or
epithelial or lesion$1 or malignan$ or nodule$1) adj2 (skin or epiderm$ or cutaneous)).ti,ab.
10 (BCC or cscc).mp. or NMSC.ti,ab.
11 keratinocyte.ti,ab.
12 keratinocy$.ti,ab.
13 or/1-12
14 dermoscop$.ti,ab.
15 dermatoscop$.ti,ab.
16 photomicrograph$.ti,ab.
17 *epiluminescence microscopy/
18 (epiluminescence adj2 microscop$).ti,ab.
19 (confocal adj2 microscop$).ti,ab.
20 (incident light adj2 microscop$).ti,ab.
21 (surface adj2 microscop$).ti,ab.
22 (visual adj (inspect$ or examin$)).ti,ab.
23 ((clinical or physical) adj examin$).ti,ab.
24 3 point.ti,ab.
25 three point.ti,ab.
26 pattern analys$.ti,ab.
27 ABCD$.ti,ab.
28 menzies.ti,ab.
29 7 point.ti,ab.
30 seven point.ti,ab.
31 (digital adj2 (dermoscop$ or dermatoscop$)).ti,ab.
32 artificial intelligence.ti,ab.
33 AI.ti,ab.
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34 computer assisted.ti,ab.
35 computer aided.ti,ab.
36 neural network$.ti,ab.
37 MoleMax.ti,ab.
38 exp diagnosis, computer-assisted/
39 image process$.ti,ab.
40 automatic classif$.ti,ab.
41 image analysis.ti,ab.
42 SIAscop$.ti,ab.
43 (optical adj2 scan$).ti,ab.
44 Aura.ti,ab.
45 MelaFind.ti,ab.
46 SIMSYS.ti,ab.
47 MoleMate.ti,ab.
48 SolarScan.ti,ab.
49 VivaScope.ti,ab.
50 confocal microscop$.ti,ab.
51 (high adj3 ultraso$).ti,ab.
52 (canine adj2 detect$).ti,ab.
53 ((mobile or cell$ or cellular or smart) adj ((phone$1 adj2 app$1) or application$1)).ti,ab.
54 smartphone$.ti,ab.
55 (DermoScan or SkinVision or DermLink or SpotCheck).ti,ab.
56 Spot Check.ti,ab.
57 Mole Detective.ti,ab.
58 (mole$1 adj2 map$).ti,ab.
59 (total adj2 body).ti,ab.
60 exfoliative cytolog$.ti,ab.
61 digital analys$.ti,ab.
62 (image$1 adj3 software).ti,ab.
63 (optical coherence adj (technolog$ or tomog$)).ti,ab.
64 (teledermatolog$ or tele-dermatolog$ or telederm or tele-derm or teledermoscop$ or tele-dermoscop$ or teledermatoscop$).mp. or
tele-dermatoscop$.ti,ab.
65 (computer adj2 diagnos$).ti,ab.
66 *sentinel lymph node biopsy/
67 (sentinel adj2 node).ti,ab.
68 nevisense.ti,ab.
69 HFUS.ti,ab.
70 electrical impedance spectroscopy.ti,ab.
71 history taking.ti,ab.
72 patient history.ti,ab.
73 (naked eye adj (exam$ or assess$)).ti,ab.
74 (skin adj exam$).ti,ab.
75 *physical examination/
76 ugly duckling.ti,ab.
77 UD sign$.ti,ab.
78 ((physician$ or clinical or physical) adj (exam$ or recog$ or triage)).ti,ab.
79 ABCDE.ti,ab.
80 clinical accuracy.ti,ab.
81 *general practice/
82 (confocal adj2 microscop$).ti,ab.
83 clinical competence/
84 diagnostic algorithm$.ti,ab.
85 checklist$1.ti,ab.
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86 virtual image$1.ti,ab.
87 volatile organic compound$1.ti,ab.
88 VOC.ti,ab.
89 dog$1.ti,ab.
90 gene expression analys$.ti,ab.
91 reflex transmission imaging.ti,ab.
92 thermal imaging.ti,ab.
93 elastography.ti,ab.
94 dog$1.ti,ab.
95 gene expression analys$.ti,ab.
96 reflex transmission imaging.ti,ab.
97 thermal imaging.ti,ab.
98 elastography.ti,ab.
99 or/14-93
100 PET-CT.ti,ab.
101 (CT or PET).ti,ab.
102 (FDG or F18 or Fluorodeoxyglucose or radiopharmaceutical$).ti,ab.
103 exp Deoxyglucose/
104 CATSCAN.ti,ab.
105 deoxyglucose.ti,ab.
106 deoxy-glucose.ti,ab.
107 *positron emission tomography/
108 *computer assisted tomography/
109 positron emission tomograph$.ti,ab.
110 *nuclear magnetic resonance imaging/
111 (MRI or fMRI or NMRI or scintigraph$).ti,ab.
112 *echography/
113 Doppler.ti,ab.
114 sonograph$.ti,ab.
115 ultraso$.ti,ab.
116 magnetic resonance imag$.ti,ab.
117 or/100-116
118 (stage$ or staging or metasta$ or recurrence or sensitivity or specificity or false negative$ or thickness$).ti,ab.
119 “Sensitivity and Specificity”/
120 *cancer staging/
121 or/118-120
122 117 and 121
123 99 or 122
124 13 and 123
Database: Cochrane Library (Wiley) 2016 searched 30 August 2016 CDSR Issue 8 of 12 2016 CENTRAL Issue 7 of 12 2016
HTA Issue 3 of 4 July 2016 DARE Issue 3 of 4 2015
Search strategy:
#1 melanoma* or nonmelanoma* or non-melanoma* or melanocyt* or non-melanocyt* or nonmelanocyt* or keratinocyte*
#2 MeSH descriptor: [Melanoma] explode all trees
#3 “skin cancer*”
#4 MeSH descriptor: [Skin Neoplasms] explode all trees
#5 skin near/2 (cancer* or carcinoma* or mass or masses or tumour* or tumor* or neoplasm* or adenoma* or epithelioma* or lesion*
or malignan* or nodule*)
#6 nmsc
#7 “squamous cell” near/2 (cancer* or carcinoma* or mass or masses or tumour* or tumor* or neoplasm* or adenoma* or epithelioma*
or lesion* or malignan* or nodule*) near/2 (skin or epiderm* or cutaneous)
#8 “basal cell” near/2 (cancer* or carcinoma* or mass or masses or tumour* or tumor* or neoplasm* or adenoma* or epithelioma* or
lesion* or malignan* or nodule*)
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#9 pigmented near/2 (lesion* or nevus or mole* or naevi or naevus or nevi or skin)
#10 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9
#11 dermoscop*
#12 dermatoscop*
#13 Photomicrograph*
#14 MeSH descriptor: [Dermoscopy] explode all trees
#15 confocal near/2 microscop*
#16 epiluminescence near/2 microscop*
#17 incident next light near/2 microscop*
#18 surface near/2 microscop*
#19 “visual inspect*”
#20 “visual exam*”
#21 (clinical or physical) next (exam*)
#22 “3 point”
#23 “three point”
#24 “pattern analys*”
#25 ABDC
#26 menzies
#27 “7 point”
#28 “seven point”
#29 digital near/2 (dermoscop* or dermatoscop*)
#30 “artificial intelligence”
#31 “AI”
#32 “computer assisted”
#33 “computer aided”
#34 AI
#35 “neural network*”
#36 MoleMax
#37 “computer diagnosis”
#38 “image process*”
#39 “automatic classif*”
#40 SIAscope
#41 “image analysis”
#42 “optical near/2 scan*”
#43 Aura
#44 MelaFind
#45 SIMSYS
#46 MoleMate
#47 SolarScan
#48 Vivascope
#49 “confocal microscopy”
#50 high near/3 ultraso*
#51 canine near/2 detect*
#52 Mole* near/2 map*
#53 total near/2 body
#54 mobile* or smart near/2 phone*
#55 cell next phone*
#56 smartphone*
#57 “mitotic index”
#58 DermoScan or SkinVision or DermLink or SpotCheck
#59 “Mole Detective”
#60 “Spot Check”
#61 mole* near/2 map*
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#62 total near/2 body
#63 “exfoliative cytolog*”
#64 “digital analys*”
#65 image near/3 software
#66 teledermatolog* or tele-dermatolog* or telederm or tele-derm or teledermoscop* or tele-dermoscop* or teledermatoscop* or tele-
dermatolog*
#67 “optical coherence” next (technolog* or tomog*)
#68 computer near/2 diagnos*
#69 sentinel near/2 node*
#70 #11 or #12 or #13 or #14 or #15 or #16 or #17 or #18 or #19 or #20 or #21 or #22 or #23 or #24 or #25 or #26 or #27 or #28
or #29 or #30 or #31 or #32 or #33 or #34 or #35 or #36 or #37 or #38 or #39 or #40 or #41 or #42 or #43 or #44 or #45 or #46 or
#47 or #48 or #49 or #50 or #51 or #52 or #53 or #54 or #55 or #56 or #57 or #58 or #59 or #60 or #61 or #62 or #63 or #64 or #
65 or #66 or #67 or #68 or #69
#71 ultraso*
#72 sonograph*
#73 MeSH descriptor: [Ultrasonography] explode all trees
#74 Doppler
#75 CT or PET or PET-CT
#76 “CAT SCAN” or “CATSCAN”
#77 MeSH descriptor: [Positron-Emission Tomography] explode all trees
#78 MeSH descriptor: [Tomography, X-Ray Computed] explode all trees
#79 MRI
#80 MeSH descriptor: [Magnetic Resonance Imaging] explode all trees
#81 MRI or fMRI or NMRI or scintigraph*
#82 “magnetic resonance imag*”
#83 MeSH descriptor: [Deoxyglucose] explode all trees
#84 deoxyglucose or deoxy-glucose
#85 “positron emission tomograph*”
#86 #71 or #72 or #73 or #74 or #75 or #76 or #77 or #78 or #79 or #80 or #81 or #82 or #83 or #84 or #85
#87 stage* or staging or metasta* or recurrence or sensitivity or specificity or “false negative*” or thickness*
#88 MeSH descriptor: [Neoplasm Staging] explode all trees
#89 #87 or #88
#90 #89 and #86
#91 #70 or #90
#92 #10 and #91
#93 BCC or CSCC or NMCS
#94 keratinocy*
#95 #93 or #94
#96 #10 or #95
#97 nevisense
#98 HFUS
#99 “electrical impedance spectroscopy”
#100 “history taking”
#101 “patient history”
#102 naked next eye near/1 (exam* or assess*)
#103 skin next exam*
#104 “ugly duckling” or (UD sign*)
#105 MeSH descriptor: [Physical Examination] explode all trees
#106 (physician* or clinical or physical) near/1 (exam* or recog* or triage*)
#107 ABCDE
#108 “clinical accuracy”
#109 MeSH descriptor: [General Practice] explode all trees
#110 confocal near microscop*
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#111 “diagnostic algorithm*”
#112 MeSH descriptor: [Clinical Competence] explode all trees
#113 checklist*
#114 “virtual image*”
#115 “volatile organic compound*”
#116 dog or dogs
#117 VOC
#118 “gene expression analys*”
#119 “reflex transmission imaging”
#120 “thermal imaging”
#121 elastography
#122 #97 or #98 or #99 or #100 or #101 or #102 or #103 or #104 or #105 or #106 or #107 or #108 or #109 or #110 or #111 or #
112 or #113 or #114 or #115 or #116 or #117 or #118 or #119 or #120 or #121
#123 #70 or #122
#124 #96 and #123
#125 #96 and #90
#126 #125 or #124
#127 #10 and #126
Database: CINAHL Plus (EBSCO) 1937 to 30 August 2016
Search strategy:
S1 (MH “Melanoma”) OR (MH “Nevi and Melanomas+”)
S2 (MH “Skin Neoplasms+”)
S3 (MH “Carcinoma, Basal Cell+”)
S4 basalioma*
S5 (basal cell) N2 (cancer* or carcinoma* or mass or masses or tumor* or tumour* or neoplasm* or adenoma* or epithelioma* or
lesion* or malignan* or nodule*)
S6 (pigmented) N2 (lesion* or mole* or nevus or nevi or naevus or naevi or skin)
S7 melanom* or nonmelanoma* or non-melanoma* or melanocyt* or non-melanocyt* or nonmelanocyt*
S8 nmsc
S9 TX BCC or cscc or NMSC
S10 (MH “Keratinocytes”)
S11 keratinocyt*
S12 S1 OR S2 OR S3 OR S4 OR S5 OR S6 OR S7 OR S8 OR S9 OR S10 OR S11
S13 dermoscop* or dermatoscop* or photomicrograph* or (3 point) or (three point) or ABCD* or menzies or (7 point) or (seven
point) or AI or Molemax or SIASCOP* or Aura or MelaFind or SIMSYS or MoleMate or SolarScan or smartphone* or DermoScan
or SkinVision or DermLink or SpotCheck
S14 (epiluminescence or confocal or incident or surface) N2 (microscop*)
S15 visual N1 (inspect* or examin*)
S16 (clinical or physical) N1 (examin*)
S17 pattern analys*
S18 (digital) N2 (dermoscop* or dermatoscop*)
S19 (artificial intelligence)
S20 (computer) N2 (assisted or aided)
S21 (neural network*)
S22 (MH “Diagnosis, Computer Assisted+”)
S23 (image process*)
S24 (automatic classif*)
S25 (image analysis)
S26 SIAScop*
S27 (optical) N2 (scan*)
S28 (high) N3 (ultraso*)
S29 elastography
S30 (mobile or cell or cellular or smart) N2 (phone*) N2 (app or application*)
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S31 (mole*) N2 (map*)
S32 total N2 body
S33 exfoliative cytolog*
S34 digital analys*
S35 image N3 software
S36 teledermatolog* or tele-dermatolog* or telederm or tele-derm or teledermoscop* or tele-dermoscop* or teledermatoscop* or tele-
dermatoscop* teledermatolog* or tele-dermatolog* or telederm or tele-derm or teledermoscop*
S37 (optical coherence) N1 (technolog* or tomog*)
S38 computer N2 diagnos*
S39 sentinel N2 node
S40 (MH “Sentinel Lymph Node Biopsy”)
S41 nevisense or HFUS or checklist* or VOC or dog*
S42 electrical impedance spectroscopy
S43 history taking
S44 “Patient history”
S45 naked eye
S46 skin exam*
S47 physical exam*
S48 ugly duckling
S49 UD sign*
S50 (physician* or clinical or physical) N1 (exam*)
S51 clinical accuracy
S52 general practice
S53 (physician* or clinical or physical) N1 (recog* or triage)
S54 confocal microscop*
S55 clinical competence
S56 diagnostic algorithm*
S57 checklist*
S58 virtual image*
S59 volatile organic compound*
S60 gene expression analys*
S61 reflex transmission imag*
S62 thermal imaging
S63 S13 or S14 or S15 OR S16 OR S17 OR S18 OR S19 OR S20 OR S21 OR S22 OR S23 OR S24 OR S25 OR S26 OR S27 OR
S28 OR S29 OR S30 OR S31 OR S32 OR S33 OR S34 OR S35 OR S36 OR S37 OR S38 OR S39 OR S40 OR S41 OR S42 OR
S43 OR S44 OR S45 OR S46 OR S47 OR S48 OR S49 OR S50 OR S51 OR S52 OR S53 OR S54 OR S55 OR S56 OR S57 OR
S58 OR S59 OR S60 OR S61 OR S62
S64 CT or PET
S65 PET-CT
S66 FDG or F18 or Fluorodeoxyglucose or radiopharmaceutical*
S67 (MH “Deoxyglucose+”)
S68 deoxy-glucose or deoxyglucose
S69 CATSCAN
S70 CAT-SCAN
S71 (MH “Deoxyglucose+”)
S72 (MH “Tomography, Emission-Computed+”)
S73 (MH “Tomography, X-Ray Computed”)
S74 positron emission tomograph*
S75 (MH “Magnetic Resonance Imaging+”)
S76 MRI or fMRI or NMRI or scintigraph*
S77 echography
S78 doppler
S79 sonograph*
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S80 ultraso*
S81 magnetic resonance imag*
S82 S64 OR S65 OR S66 OR S67 OR S68 OR S69 OR S70 OR S71 OR S72 OR S73 OR S74 OR S75 OR S76 OR S77 OR S78
OR S79 OR S80 OR S81
S83 stage* or staging or metasta* or recurrence or sensitivity or specificity or (false negative*) or thickness
S84 (MH “Neoplasm Staging”)
S85 S83 OR S84
S86 S82 AND S85
S87 S63 OR S86
S88 S12 AND S87
Database: Science Citation Index SCI Expanded (Web of Science) 1900 to 30 August 2016
Conference Proceedings Citation Index (Web of Science) 1900 to 1 September 2016
Search strategy:
#1 (melanom* or nonmelanom* or non-melanoma* or melanocyt* or non-melanocyt* or nonmelanocyt* or keratinocyt*)
#2 (basalioma*)
#3 ((skin) near/2 (cancer* or carcinoma or mass or masses or tumour* or tumor* or neoplasm* or adenoma* or epithelioma* or lesion*
or malignan* or nodule*))
#4 ((basal) near/2 (cancer* or carcinoma* or mass or masses or tumour* or tumor* or neoplasm* or adenoma* or epithelioma* or
lesion* or malignan* or nodule*))
#5 ((pigmented) near/2 (lesion* or mole* or nevus or nevi or naevus or naevi or skin))
#6 (nmsc or BCC or NMSC or keratinocy*)
#7 ((squamous cell (cancer* or carcinoma* or mass or masses or tumour* or tumor* or neoplasm* or adenoma* or epithelioma* or
lesion* or malignan* or nodule*))
#8 (skin or epiderm* or cutaneous)
#9 #8 AND #7
#10 #9 OR #6 OR #5 OR #4 OR #3 OR #2 OR #1
#11 ((dermoscop* or dermatoscop* or photomicrograph* or epiluminescence or confocal or “incident light” or “surface microscop*”
or “visual inspect*” or “physical exam*” or 3 point or three point or pattern analy* or ABCDE or menzies or 7 point or seven point
or dermoscop* or dermatoscop* or AI or artificial or computer aided or computer assisted or neural network* or Molemax or image
process* or automatic classif* or image analysis or siascope or optical scan* or Aura or melafind or simsys or molemate or solarscan or
vivascope or confocal microscop* or high ultraso* or canine detect* or cellphone* or mobile* or phone* or smartphone or dermoscan
or skinvision or dermlink or spotcheck or spot check or mole detective or mole map* or total body or exfoliative psychology or digital
or image software or optical coherence or teledermatology or telederm* or teledermoscop* or teledermatoscop* or computer diagnos*
or sentinel))
#12 ((nevisense or HFUS or impedance spectroscopy or history taking or patient history or naked eye or skin exam* or physical exam*
or ugly duckling or UD sign* or physician* exam* or physical exam* or ABCDE or clinical accuracy or general practice or confocal
microscop* or clinical competence or diagnostic algorithm* or checklist* or virtual image* or volatile organic or VOC or dog* or gene
expression or reflex transmission or thermal imag* or elastography))
#13 #11 or #12
#14 ((PET or CT or FDG or deoxyglucose or deoxy-glucose or fluorodeoxy* or radiopharma* or CATSCAN or positron emission or
computer assisted or nuclear magnetic or MRI or FMRI or NMRI or scintigraph* or echograph* or Doppler or sonograph* or ultraso*
or magnetic reson*))
#15 ((stage* or staging or metast* or recurrence or sensitivity or specificity or false negative* or thickness*))
#16 #14 AND #15
#17 #16 OR #13
#18 #10 AND #17
Refined by: DOCUMENT TYPES: (MEETING ABSTRACT OR PROCEEDINGS PAPER)
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Appendix 6. Full text inclusion criteria
Criterion Inclusion Exclusion
Study design For diagnostic and staging reviews
• Any study for which a 2×2 contingency table
can be extracted, e.g.
◦ diagnostic case control studies
◦ ’cross-sectional’ test accuracy study with
retrospective or prospective data collection
◦ studies where estimation of test accuracy
was not the primary objective but test results for
both index and reference standard were available
◦ RCTs of tests or testing strategies where
participants were randomised between index tests
and all undergo a reference standard (i.e. accuracy
RCTs)
• < 5 melanoma cases (diagnosis reviews)
• < 10 participants (staging reviews)
• Studies developing new criteria for diagnosis
unless a separate ’test set’ of images were used to
evaluate the criteria (mainly digital dermoscopy)
• Studies using ’normal’ skin as controls
• Letters, editorials, comment papers, narrative
reviews
• Insufficient data to construct a 2×2 table
Target condition • Melanoma
• Keratinocyte skin cancer (or non-melanoma
skin cancer)
◦ BCC or epithelioma
◦ cSCC
• Studies exclusively conducted in children
• Studies of non-cutaneous melanoma or SCC
Population For diagnostic reviews
• Adults with a skin lesion suspicious for
melanoma, BCC, or cSCC (other terms include
pigmented skin lesion/nevi, melanocytic,
keratinocyte, etc.)
• Adults at high risk of developing melanoma
skin cancer, BCC, or cSCC
For staging reviews
• Adults with a diagnosis of melanoma or cSCC
undergoing tests for staging of lymph nodes or
distant metastases or both
• People suspected of other forms of skin cancer
• Studies conducted exclusively in children
Index tests For diagnosis
• Visual inspection/clinical examination
• Dermoscopy/dermatoscopy
• Teledermoscpoy
• Smartphone/mobile phone applications
• Digital dermoscopy/artificial intelligence
• Confocal microscopy
• Ocular coherence tomography
• Exfoliative cytology
• High-frequency ultrasound
• Canine odour detection
• DNA expression analysis/gene chip analysis
• Other
For staging
• Sentinel lymph biopsy for therapeutic rather
than staging purposes
• Tests to determine melanoma thickness
• Tests to determine surgical margins/lesion
borders
• Tests to improve histopathology diagnose
• LND
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(Continued)
• CT
• PET
• PET-CT
• MRI
• Ultrasound +/fine needle aspiration cytology
FNAC
• SLNB +/high-frequency ultrasound
• Other
Any test combination and in any order
Any test positivity threshold
Any variation in testing procedure (e.g. radioisotope
used)
Reference standard For diagnostic studies
• Histopathology of the excised lesion
• Clinical follow-up of non-excised/benign
appearing lesions with later histopathology if
suspicious
• Expert diagnosis (studies should not be
included if expert diagnosis is the sole reference
standard)
For studies of imaging tests for staging
• Histopathology (via LND or SLMB)
• Clinical/radiological follow-up
• A combination of the above
For studies of SLNB accuracy for staging
• LND of both SLN+ and SLn participants to
identify all diseased nodes
• LND of SLN+ participants and follow-up of
SLN participants to identify a subsequent nodal
recurrence in a previously investigated nodal basin
For diagnostic studies
• Exclude if any disease positive participants have
diagnosis unconfirmed by histology
• Exclude if > 50% of disease negative
participants have diagnosis confirmed by expert
opinion with no histology or follow-up
• Exclude studies of referral accuracy, i.e.
comparing referral decision with expert diagnosis,
unless evaluations of teledermatology or mobile
phone applications
BCC: basal cell carcinoma; cSCC: cutaneous squamous cell carcinoma; CT: computed tomography; FNAC: fine needle aspiration
cytology; LND: lymph node dissection; MRI: magnetic resonance imaging; PET: positron emission tomography; PET-CT: positron
emission tomography computed tomography; RCT: randomised controlled trial; SCC: squamous cell carcinoma; SLN+: positive
sentinel lymph node; SLn: negative sentinel lymph node; SLNB: sentinel lymph node biopsy
Appendix 7. Quality assessment (based on QUADAS-2)
The QUADAS-2 checklist (Whiting 2011) was tailored to the review topic as follows below.
Patient selection domain (1)
Selective recruitment of study participants can be a key influence on test accuracy. In general terms, all participants eligible to undergo
a test should be included in a study, allowing for the intended use of that test within the context of the study. We considered studies that
separately sampled malignant and benign lesions to have used a case-control design; and those that supplemented a series of suspicious
lesions with additional malignant or benign lesions to be at unclear risk of bias.
In terms of exclusions, we considered studies that excluded particular lesion types (e.g. lentigo maligna), particular lesion sites, or other
lesions on the basis of image quality or lack of observer agreement (e.g. on histopathology) to be at high risk of bias.
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In judging the applicability of patient populations to the review question, we considered restriction to particular lesion populations,
such as melanocytic, nodular, high risk or restrictions by size to be of high concern for applicability.
Given that diagnosis of skin cancer is primarily lesion-based, there is the potential for study participants with multiple lesions to
contribute disproportionately to estimates of test accuracy, especially if they are at particular risk of having skin cancer. We considered
studies that include a high number of lesions in relation to the number of participants in the study to be less representative than studies
conducted in a more general population of participants (i.e. if the difference between the number of included lesions and number of
included participants is greater than 5%).
Index test domain (2)
Given the potential for subjective differences in test interpretation for melanoma, the interpretation of the index test blinded to the
result of the reference standard is a key means of reducing bias. For prospective studies and retrospective studies that used the original
index test interpretation, the diagnosis will by nature be interpreted and recorded before the result of the reference standard is known;
however, studies using previously acquired images could be particularly susceptible to information bias. For these studies to be at low
risk of bias, we required a clear indication that observers were unaware of the reference standard diagnosis at time of test interpretation.
We also added an item to assess the presence of blinding between interpretations of different algorithms; however, we did not include
this item in the overall assessment of risk of bias.
Pre-specification of the index test threshold was considered present if the study clearly reported that the threshold used was not data
driven, i.e. was not based on study results. Studies that did not clearly describe the threshold used but that required clinicians to record
a diagnosis or management decision for a lesion were considered to be unclear on this criterion. Studies reporting accuracy for multiple
numeric thresholds, where ROC analysis was used to select the threshold, or that reported accuracy for the presence of independently
significant lesion characteristics with no separate test set of lesions were considered at high risk of bias.
In terms of applicability of the index test to the review question, we required the test to be applied and interpreted as it would be in
a clinical practice setting, i.e. in-person or face-to-face with the patient, and by a single observer as opposed to a consensus decision
or average across multiple observers. Image-based studies were considered to be of high concern, although for some tests (e.g. RCM)
image interpretations where the observer was also supplied with a clinical or dermoscopic image of the lesion along with some patient
characteristics were considered ’unclear’.
Despite the often subjective nature of test interpretation, it is also important for study authors to outline the particular lesion character-
istics that were considered to be indicative of melanoma, particularly where established algorithms or checklists were not used. Studies
were considered of low concern if the threshold used was established in a prior study or sufficient threshold details were presented to
allow replication.
The experience of the examiner will also impact on the applicability of study results. We required studies to describe the test interpreter
as ’experienced’ or ’expert’ to have low concern about applicability.
Reference standard domain (3)
In an ideal study, consecutively recruited participants should all undergo incisional or excisional biopsy of the skin lesion regardless of
level of clinical suspicion of melanoma. In reality, both partial and differential verification bias are likely. Partial verification bias may
occur where histology is the only reference standard used, and only those participants with a certain degree of suspicion of malignancy
based on the result of the index test undergo verification, the others either being excluded from the study or defined as being disease-
negative without further assessment or follow-up, as discussed above.
Differential verification bias will be present where other reference standards are used in addition to histological verification of suspicious
lesions. A typical example of verification bias in skin cancer occurs when investigators do not biopsy people with benign-appearing
lesions but instead follow them up for a period of time to determine whether any malignancy subsequently develops (these would be
false-negatives on the index test). We defined an ’adequate’ reference standard as: all disease-positive individuals having a histological
reference standard either at the time of application of the index test or after a period of clinical follow-up; and at least 80% of disease-
negative participants have received a histological diagnosis, with up to 20% undergoing at least three months’ follow-up of benign-
appearing lesions.
A further challenge is the potential for incorporation bias, i.e. where the result of the index test is used to help determine the reference
standard diagnosis. It is normal practice for the clinical diagnosis (usually by visual inspection or dermoscopy) to be included on
pathology request forms and for the histopathologist to use this diagnosis to help with the pathology interpretation. Although inclusion
of such clinical information on the histopathology request form is theoretically a form of incorporation bias, blinded interpretation
of the histopathology reference standard is not normal practice, and enforcement of such conditions would significantly limit the
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generalisability of the study results. For studies evaluating tests other than visual inspection or dermoscopy, this item was divided into
two questions, firstly whether the reference standard was blinded to the index test result, and secondly whether it was blinded to the
clinical diagnosis. Only the response to the first part (i.e. blinding to index test) was included in our overall assessment of risk of bias
for the reference standard domain.
In judging the applicability of the reference standard to our review question, scored studies as high concern around applicability if
they used expert diagnosis (with no follow-up) as a reference standard in any patient, or did not report histology interpretation by a
dermatopathologist.
Flow and timing domain (4)
In the ideal study, the diagnosis based on the index test and reference standard should be made consecutively or as near to each other in
time as possible to avoid changes in lesion over time. For lesions with a histological reference standard, we have defined a one-month
period as an appropriate interval between application of the index test and the reference standard. For studies using clinical follow-up,
a minimum three-month follow-up period has been defined as at low risk of bias for detecting false-negatives. This interval was chosen
based on a study showing that most false-negative melanomas will be diagnosed within three months of the initial negative index test
although a small number will be diagnosed up to 12 months subsequently (Altamura 2008).
In assessing whether all patients were included in the analysis, we considered studies at high risk of bias if participants were excluded
following recruitment.
Comparative domain
A comparative domain was added to the QUADAS-2 checklist for studies comparing the accuracy of RCM and dermoscopy. Items
were included to assess the presence blinding of interpretation between tests, and to specify a maximum of one month interval between
application of index tests, as intervals greater than these may be accompanied by changes in tumour characteristics. As it would not be
normal practice for RCM to be interpreted blinded to the clinical or dermoscopic diagnosis, the scoring of this item did not contribute
to our overall assessment of risk of bias. We also considered whether both tests were applied and interpreted in a clinically applicable
manner.
The following tables use text that was originally published in the QUADAS-2 tool by Whiting and colleagues (Whiting 2011).
Item Response (delete as required)
PARTICIPANT SELECTION (1) - RISK OF BIAS
1) Was a consecutive or random sample of participants or images
enrolled?
Yes - if paper states consecutive or random
No - if paper describes other method of sampling
Unclear - if participant sampling not described
2) Was a case-control design avoided? Yes - if consecutive or random or case-control design clearly not
used
No - if study described as case-control or describes sampling spe-
cific numbers of participants with particular diagnoses
Unclear - if not described
3) Did the study avoid inappropriate exclusions, e.g.
• ’difficult to diagnose’ lesions not excluded
• lesions not excluded on basis of disagreement between
evaluators
Yes - if inappropriate exclusions were avoided
No - if lesions were excluded that might affect test accuracy, e.
g. ’difficult to diagnose’ lesions, or where disagreement between
evaluators was observed
Unclear - if not clearly reported but there is suspicion that difficult
to diagnose lesions may have been excluded
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(Continued)
4) For between-person comparative studies only (i.e. allocating
different tests to different study participants):
• A) were the same participant selection criteria used for
those allocated to each test?
• B) was the potential for biased allocation between tests
avoided through adequate generation of a randomised sequence?
• C) was the potential for biased allocation between tests
avoided through concealment of allocation prior to assignment?
For A)
• Yes - if same selection criteria were used for each index test,
No - if different selection criteria were used for each index test,
Unclear - if selection criteria per test were not described, NA - if
only 1 index test was evaluated or all participants received all tests
For B)
• Yes - if adequate randomisation procedures are described,
No - if inadequate randomisation procedures are described,
Unclear - if the method of allocation to groups is not described
(a description of ’random’ or ’randomised’ is insufficient), NA -
if only 1 index test was evaluated or all participants received all
tests
For C)
• Yes - if appropriate methods of allocation concealment are
described, No - if appropriate methods of allocation concealment
are not described, Unclear - if the method of allocation
concealment is not described (sufficient detail to allow a definite
judgement is required), NA - if only 1 index test was evaluated
Could the selection of participants have introduced bias?
For non-comparative and within person-comparative studies
1. If answers to all of questions 1), 2), and 3) ’Yes’:
2. If answers to any 1 of questions 1), 2), or 3) ’No’:
3. If answers to any 1 of questions 1), 2), or 3) ’Unclear’:
For between-person comparative studies
1. If answers to all of questions 1), 2), 3), and 4) ’Yes’:
2. If answers to any 1 of questions 1), 2), 3), or 4) ’No’:
3. If answers to any 1 of questions 1), 2), 3), or 4) ’Unclear’:
For non-comparative and within person-comparative studies
1. Risk is low
2. Risk is high
3. Risk unclear
For between-person comparative studies
1. Risk is low
2. Risk is high
3. Risk unclear
PARTICIPANT SELECTION (1) - CONCERNS REGARDING APPLICABILITY
1) Are the included participants and chosen study setting appro-
priate to answer the review question, i.e. are the study results gen-
eralisable?
• This item is not asking whether exclusion of certain
participant groups might bias the study’s results (as in ’Risk of
bias’ above), but is asking whether the chosen study participants
and setting are appropriate to answer our review question.
Because we are looking to establish test accuracy in both primary
presentation and referred participants, a study could be
appropriate for 1 setting and not for the other, or it could be
unclear as to whether the study can appropriately answer either
question
• For each study assessed, please consider whether it is more
relevant for A) participants with a primary presentation of a skin
lesion or B) referred participants, and respond to the questions
in either A) or B) accordingly. If the study gives insufficient
details, please respond Unclear to both parts of the question
A) For studies that will contribute to the analysis of partic-
ipants with a primary presentation of a skin lesion (i.e. test
naive)
Yes - if participants included in the study appear to be generally
representative of those who might present in a usual practice set-
ting
No - if study participants appear to be unrepresentative of usual
practice, e.g. in terms of severity of disease, demographic features,
presence of differential diagnosis or comorbidity, setting of the
study, and previous testing protocols
Unclear - if insufficient details are provided to determine the
generalisability of study participants
B) For studies that will contribute to the analysis of referred
participants (i.e. who have already undergone some form of
testing)
Yes - if study participants appear to be representative of those who
might be referred for further investigation. If the study focuses
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only on those with equivocal lesions, for example, we would sug-
gest that this is not representative of the wider referred population
No - if study participants appear to be unrepresentative of usual
practice, e.g. if a particularly high proportion of participants have
been self-referred or referred for cosmetic reasons. Other factors
to consider include severity of disease, demographic features, pres-
ence of differential diagnosis or comorbidity, setting of the study,
and previous testing protocols
Unclear - if insufficient details are provided to determine the
generalisability of study participants
2) Did the study avoid including participants with multiple le-
sions?
Yes - if the difference between the number of included lesions and
number of included participants is less than 5%
No - if the difference between the number of included lesions and
number of included participants is greater than 5%
Unclear - if it is not possible to assess
Is there concern that the included participants do not match the
review question?
1. If the answer to question 1) or 2) ’Yes’:
2. If the answer to question 1) or 2) ’No’:
3. If the answer to question 1) or 2) ’Unclear’:
1. Concern is low
2. Concern is high
3. Concern is unclear
INDEX TEST (2) - RISK OF BIAS (to be completed per test evaluated)
1) Was the index test or testing strategy result interpreted without
knowledge of the results of the reference standard?
Yes - if index test described as interpreted without knowledge of
reference standard result or, for prospective studies, if index test is
always conducted and interpreted prior to the reference standard
No - if index test described as interpreted in knowledge of reference
standard result
Unclear - if index test blinding is not described
2) Was the diagnostic threshold at which the test was considered
positive (i.e. melanoma present) prespecified?
Yes - if threshold was prespecified (i.e. prior to analysing study
results)
No - if threshold was not prespecified
Unclear - if not possible to tell whether or not diagnostic threshold
was prespecified
3) For within-person comparisons of index tests or testing strate-
gies (i.e. > 1 index test applied per participant): was each index
test result interpreted without knowledge of the results of other
index tests or testing strategies?
Yes - if all index tests were described as interpreted without knowl-
edge of the results of the others
No - if the index tests were described as interpreted in the knowl-
edge of the results of the others
Unclear - if it is not possible to tell whether knowledge of other
index tests could have influenced test interpretation
NA - if only 1 index test was evaluated
Could the conduct or interpretation of the index test have intro-
duced bias?
For non-comparative and between-person comparison studies
For non-comparative and between-person comparison studies
1. Risk is low
2. Risk is high
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1. If answers to questions 1) and 2) ’Yes’:
2. If answers to either questions 1) or 2) ’No’:
3. If answers to either questions 1) or 2) ’Unclear’:
For within-person comparative studies
1. If answers to all questions 1), 2), for any index test and 3)
’Yes’:
2. If answers to any 1 of questions 1) or 2) for any index test
or 3) ’No’:
3. If answers to any 1 of questions 1) or 2) for any index test
or 3) ’Unclear’:
3. Risk is unclear
For within-person comparative studies
1. Risk is low
2. Risk is high
3. Risk is unclear
INDEX TEST (2) - CONCERN ABOUT APPLICABILITY
1) Was the diagnostic threshold to determine presence or absence
of disease established in a previously published study?
E.g. previously evaluated/established
• algorithm/checklist used
• lesion characteristics indicative of melanoma used
• objective (usually numerical) threshold used
Yes - if a previously evaluated/established tool to aid diagnosis
of melanoma was used or if the diagnostic threshold used was
established in a previously published study
No - if an unfamiliar/new tool to aid diagnosis of melanoma
was used, if no particular algorithm was used, or if the objective
threshold reportedwas chosenbased on results in the current study
Unclear - if insufficient information was reported
2) Were thresholds or criteria for diagnosis reported in sufficient
detail to allow replication?
Study results can only be reproduced if the diagnostic threshold is
described in sufficient detail. This item applies equally to studies
using pattern recognition and those using checklists or algorithms
to aid test interpretation
Yes - If the criteria for diagnosis of melanoma were reported in
sufficient detail to allow replication
No - if the criteria for diagnosis of melanoma were not reported
in sufficient detail to allow replication
Unclear - If some but not sufficient information on criteria for
diagnosis to allow replication were provided
3) Was the test interpretation carried out by an experienced ex-
aminer?
Yes - if the test was interpreted by 1 or more speciality-accredited
dermatologists, or by examiners of any clinical background with
special interest in dermatology and with any formal training in
the use of the test
No - if the test was not interpreted by an experienced examiner
(see above)
Unclear - if the experience of the examiner(s) was not reported in
sufficient detail to judge or if examiners were described as ’Expert’
with no further detail given
NA - if system-based diagnosis, i.e. no observer interpretation
Is there concern that the index test, its conduct, or interpretation
differ from the review question?
1. If answers to questions 1), 2), and 3) ’Yes’:
2. If answers to questions 1), 2), or 3) ’No’:
3. If answers to questions 1), 2), or 3) ’Unclear’:
1. Concern is low
2. Concern is high
3. Concern is unclear
REFERENCE STANDARD (3) - RISK OF BIAS
95High-frequency ultrasound for diagnosing skin cancer in adults (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(Continued)
1) Is the reference standard likely to correctly classify the target
condition?
A) Disease-positive - 1 or more of the following:
• histological confirmation of melanoma following biopsy or
lesion excision
• clinical follow-up of benign-appearing lesions for at least 3
months following the application of the index test, leading to a
histological diagnosis of melanoma
B) Disease-negative - 1 or more of the following:
• histological confirmation of absence of melanoma
following biopsy or lesion excision in at least 80% of disease-
negative participants
• clinical follow-up of benign-appearing lesions for a
minimum of 3 months following the index test in up to 20% of
disease-negative participants
A) Disease-positive
Yes - if all participants with a final diagnosis of melanoma under-
went 1 of the listed reference standards
No - If a final diagnosis of melanoma for any participant was
reached without histopathology
Unclear - if the method of final diagnosis was not reported for
any participant with a final diagnosis of melanoma or if the length
of clinical follow-up used was not clear or if a clinical follow-up
reference standard was reported in combination with a partici-
pant-based analysis and it was not possible to determine whether
the detection of a malignant lesion during follow-up is the same
lesion that originally tested negative on the index test
B) Disease-negative
Yes - If at least 80% of benign diagnoses were reached by histology
and up to 20% were reached by clinical follow-up for a minimum
of 3 months following the index test
No - ifmore than20%of benigndiagnoseswere reachedby clinical
follow-up for a minimum of 3 months following the index test or
if clinical follow-up period was less than 3 months
Unclear - if the method of final diagnosis was not reported for
any participant with benign or non-melanoma diagnosis
2) Were the reference standard results interpreted without knowl-
edge of the results of the index test?
Please score this item for all studies even though histopathology
interpretation is usually conducted with knowledge of the clinical
diagnosis (from visual inspection or dermoscopy or both).We will
deal with this by not including the response to this item in the
’Risk of bias’ assessment for these tests. For reviews of all other
tests, this item will be retained
Yes - if the reference standard diagnosis was reached blinded to
the index test result
No - if the reference standard diagnosis was reached with knowl-
edge of the index test result
Unclear - if blinded reference test interpretation was not clearly
reported
Could the reference standard, its conduct, or its interpretation
have introduced bias?
For visual inspection/dermoscopy evaluations
1. If answer to question 1) ’Yes’:
2. If answer to question 1) ’No’:
3. If answer to question 1) ’Unclear’:
For all other tests
1. If answers to questions 1) and 2) ’Yes’:
2. If answers to questions 1) or 2) ’No’:
3. If answers to questions 1) or 2) ’Unclear’:
For visual inspection/dermoscopy evaluations
1. Risk is low
2. Risk is high
3. Risk is unclear
For all other tests
1. Risk is low
2. Risk is high
3. Risk is unclear
REFERENCE STANDARD (3) - CONCERN ABOUT APPLICABILITY
1) Are index test results presented separately for each component
of the target condition (i.e. separate results presented for those
with invasivemelanoma,melanoma in situ, lentigomaligna, severe
dysplasia, BCC, and cSCC)?
Yes - if index test results for each component of the target condition
can be disaggregated
No - if index test results for the different components of the target
condition cannot be disaggregated
Unclear - if not clearly reported
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2) Expert opinion (with no histological confirmation) was not
used as a reference standard
’Expert opinion’ means diagnosis based on the standard clinical
examination, with no histology or lesion follow-up
***do not complete this item for teledermatology studies
Yes - if expert opinion was not used as a reference standard for
any participant
No - if expert opinion was used as a reference standard for any
participant
Unclear - if not clearly reported
3) Was histology interpretation carried out by an experienced
histopathologist or by a dermatopathologist?
Yes - if histology interpretation was reported to be carried out by
an experienced histopathologist or dermatopathologist
No - if histology interpretation was reported to be carried out by
a less experienced histopathologist
Unclear - if the experience/qualifications of the pathologist were
not reported
Is there concern that the target condition as defined by the refer-
ence standard does not match the review question?
1. If answers to all questions 1), 2), and 3) ’Yes’:
2. If answers to any 1 of questions 1), 2), or 3) ’No’:
3. If answers to any 1 of questions 1), 2), or 3) ’Unclear’:
***For teledermatology studies only
1. If answers to all questions 1) and 3) ’Yes’:
2. If answers to questions 1) or 3) ’No’:
3. If answers to questions 1) or 3) ’Unclear’:
1. Concern is low
2. Concern is high
3. Concern is unclear
***For teledermatology studies only
1. Concern is low
2. Concern is high
3. Concern is unclear
FLOW AND TIMING (4): RISK OF BIAS
1) Was there an appropriate interval between index test and ref-
erence standard?
A) For histopathological reference standard, was the interval be-
tween index test and reference standard ≤ 1 month?
B) If the reference standard includes clinical follow-up of border-
line/benign-appearing lesions, was there at least 3 months’ follow-
up following application of index test(s)?
A)
Yes - if study reports ≤ 1 month between index and reference
standard
No - if study reports > 1 month between index and reference
standard
Unclear - if study does not report interval between index and
reference standard
B)
Yes - if study reports ≥ 3 months’ follow-up
No - if study reports < 3 months’ follow-up
Unclear - if study does not report the length of clinical follow-up
2) Did all participants receive the same reference standard? Yes - if all participants underwent the same reference standard
No - if more than 1 reference standard was used
Unclear - if not clearly reported
3) Were all participants included in the analysis? Yes - if all participants were included in the analysis
No - if some participants were excluded from the analysis
Unclear- if not clearly reported
4) For within-person comparisons of index tests
Was the interval between application of index tests ≤ 1 month?
Yes - if study reports ≤ 1 month between index tests
No - if study reports > 1 month between index tests
Unclear - if study does not report the interval between index tests
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Could the participant flow have introduced bias?
For non-comparative and between-person comparison studies
1. If answers to questions 1), 2), and 3) ’Yes’:
2. If answers to any 1 of questions 1), 2), or 3) ’No’:
3. If answers to any 1 of questions 1), 2), or 3) ’Unclear’:
For within-person comparative studies
1. If answers to all questions 1), 2), 3), and 4) ’Yes’:
2. If answers to any 1 of questions 1), 2), 3), or 4) ’No’:
3. If answers to any 1 of questions 1), 2), 3), or 4) ’Unclear’:
For non-comparative and between-person comparison studies
1. Risk is low
2. Risk is high
3. Risk is unclear
For within-person comparative studies
1. Risk is low
2. Risk is high
3. Risk is unclear
BCC: basal cell carcinoma; cSCC: cutaneous squamous cell carcinoma; NA: not applicable.
Appendix 8. Summary study details
Study au-
thor
Outcomes
reported
Study type Inclusion
criteria
Number
of patients
(lesions)
US
machine
Frequency
Resolu-
tion
Threshold Observer
qualifica-
tion
(number)
and expe-
rience
Reference
standard
Final
diagnoses
Exclu-
sions
Bessoud
2003
MEL
WPC
P-CS
France
Secondary
Patients
with PSLs
referred
from the
Derma-
tology De-
partment
to the Ul-
trasound
Unit
111 (130) AU 4 or
AU 5 Idea
(Esaote-
Biomed-
ica, Genoa,
Italy)
Doppler
20-MHz
axial 80
µm; lateral
100 µm
7 MHz
1. Hypoe-
choic, ho-
mogenous
and well
defined
HFUS +
Doppler
As above
AND
intra-le-
sional ves-
sels present
Not
described
Histology
MM 65; 4
BCC;
1neurosar-
coma
BN 33; SK
5;
Other 6 (3
melanosis,
1 throm-
bosing
capillari-
tis, 1 histi-
ocytofi-
broma, 1
lentigo)
16 ’unseen’
on ultra-
sound (16/
130=12%)
;
5
melanoma;
11 benign
nevi (in-
cluding 1
lentigo)
Further 8
lesions not
im-
aged with
Doppler
(basis for
selection
NR)
Clement
2001
BCC
WPC
P-CS
France
Secondary
Patients
with PSLs
including
melanocytic
160 (176) AU4 then
AU5 Idea,
(Esaote
Biomed-
20 MHz
80 µm ax-
ial; 100
µm lateral
1. Hypoe-
choic
2. Hypoe-
choic and
Not
described
Histology
MM 1;
BCC 23;
Mel metas-
38 not vi-
sualised,
including
two that
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and non
melanocytic
examined
before
resection
(recruited
1998-
1999)
ica, Genoa,
ltaly)
Doppler
7 MHz homoge-
nous
3. Hypoe-
choic and
well
defined
HFUS +
Doppler
Hypoe-
choic
AND vas-
cularity
present
tases 6;
BN 6; SK
29; histio-
cytofi-
broma 11;
angioma 7
were
difficult to
reach (38/
176 = 21.
6%);
5
melanoma
(all in the
horizon-
tal growth
phase; 33
benign ne-
vus)
Dummer
1995
MEL
BCC
NC
NR-CS
Germany
Secondary
Patients
with PSLs
referred
from
the outpa-
tient clinic
to the De-
partment
of Derma-
tology
NR (92) DUB 20,
Taberna
pro
Medicum,
Luneburg,
Germany
20 MHz
axial 80
µm; lateral
200 µm
1. Hypoe-
choic
2. Hypoe-
choic and
homoge-
nous
3. Hypoe-
choic and
well
defined (1)
Sharp basal
margins;
2) Sharp
lateral
margins)
Not
described
Histology
MM 108;
BCC 65
BN 307;
SK 211;
DF 54; an-
gioma 47
None
reported
Harland
2000
NC
CCS
UK
Specialist
Pa-
tients with
PSLs with
specific
presump-
tive clinical
diag-
noses (SK,
BN, MM)
from a PSL
clinic; the
referring
GP had
consid-
ered the di-
agnosis of
melanoma
for each le-
sion
NR (54) Dermas-
can-CTM
B-scanner
(Cortex
Technol-
ogy, ApS,
Hadsund,
Denmark)
20 MHz
axial 50
µm; lateral
300 µm
1. Dermal
echogenic-
ity ra-
tio (DER)
< 3 (to en-
sure sensi-
tivity of
100%)
2. Absence
of entry
echo line
(EEL) - (ei-
ther equiv-
alent to
perile-
sional skin
(non-en-
hanced) or
Not
described
Histology
MM 19;
MiS 6
BN 15; SK
29
BN
excluded
from sensi-
tivity
and speci-
ficity esti-
mates
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as broad-
ened);
3. Either 1.
Or 2.
Lassau
1997
MEL
BCC
WPC
P-CS
France
Secondary
Pa-
tients with
skin le-
sions clin-
ically sus-
pected
of being ei-
ther
melanoma
or BCC
and sched-
uled for re-
section
70 (70) Esaote-
Biomedica
AU4 Idea
(Genoa,
Italy)
Doppler
20 MHz
axial 20
µm; lateral
100 µm
7 MHz
1. Hypoe-
choic, ho-
mogenous
and well
defined
HFUS +
Doppler
As
above OR
intratu-
moral ves-
sels present
Not
described
Histology
MM 19;
BCC 31;
neurosar-
coma 1
BN 12
6/38
clinically
suspected
MEL not
visualised
on HFUS
(includ-
ing 3
melanomas)
; plus 1/32
suspected
BCCs
(which
proved
to be an
actinic
keratosis)
; (7/70 =
10%);
Rallan
2007
NC
CCS
UK
Specialist
Patients re-
ferred to a
skin cancer
clinic with
a suspicion
of
melanoma
and with a
subse-
quent clin-
i-
cal diagno-
sis of SK,
BN, or sus-
picion of
melanoma
87 (87) Dermas-
can Cv3
Cortex
ApS, Den-
mark)
; 20 MHz,
modified
for RTI
us-
ing a trans-
ducer with
an f-num-
ber of 0.95
- 1. Presence
of either
RTI con-
trast, LBI
rel-
ative het-
erogeneity,
OR EEI
rel-
ative het-
erogene-
ity; mecha-
nism/val-
ues indica-
tive
of presence
of each fea-
ture NR
Not
described
Histology
MM 14;
MiS 11
BN 38; SK
24
None
reported
NC: non comparative study; WPC: within-person comparison study; P: prospective; NR: not reported; CS: case series; CCS: case
control study;HFUS: high-frequency ultrasound;PSL: pigmented skin lesion;MEL: melanoma (invasive and in situ);MM: malignant
melanoma; MiS: melanoma in situ; BCC: basal cell carcinoma; BN: benign naevi; SK: seborrhoeic keratosis; DF: dermatofibroma;
RTI: reflex transmission imaging; LBI: lesional backscatter image; EEL: entry echo line; EEI: entry echo image; DER: dermal
echogenicity ratio; GP: general practitioner.
*Also reports in person diagnosis for VI and for Dermoscopy
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
Due to the small number of studies available, we produced a single review that evaluates the accuracy of HFUS in all skin cancers; this
replaces the two reviews intended in the protocols to address cutaneous melanoma and keratinocyte cancers.
This single review includes three primary objectives related to the detection of melanoma, BCC and cSCC. For the detection of
melanoma, we changed the primary objectives and primary target condition from detection of invasive melanoma alone, to the detection
of cutaneous invasivemelanoma and atypical intraepidermalmelanocytic variants, as the latter ismore clinically relevant to the practicing
clinician. We added another secondary objective to allow the evaluation of Doppler ultrasound in combination with high-frequency
ultrasound for skin cancer diagnosis.
Availability of data limited heterogeneity investigations and sensitivity analyses.
We amended the text to clarify that studies available only as conference abstracts would be excluded from the review unless full
papers could be identified; studies available only as conference abstracts do not allow a comprehensive assessment of study methods or
methodological quality.
Due to the early phase nature of HFUS diagnosis for skin cancer, we replaced the following text from the protocol:
“We will include studies developing new algorithms or methods of diagnosis (i.e. derivation studies) if they use a separate independent
’test set’ of participants or images to evaluate the new approach. We will also include studies using other forms of cross validation, such
as ’leave-one-out’ cross-validation (Efron 1983). We will note for future reference (but not extract) any data on the accuracy of lesion
characteristics individually, e.g. the presence or absence of a pigment network or detection of asymmetry”
with:
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“Studies should ideally evaluate a predefined ’rule’ or algorithm describing combinations of ultrasound characteristics that determine
the presence or absence of melanoma, BCC or cSCC. However, as HFUS is in a relatively early phase of development, we included
studies if we could extract 2 × 2 contingency table data based on the presence or absence of at least two ultrasound features related
to tissue morphology or acoustic properties, for example echogenicity, homogeneity of appearance and definition of margins. Studies
attempting to quantify HFUS parameters were also eligible for inclusion. There was no requirement for studies to have explicitly set
out to estimate the diagnostic accuracy of the parameters assessed.”
Although we extracted any reporting of special interest or accreditation in skin cancer according to observer expertise, we were unable
to analyse the effect on accuracy.
We proposed to supplement the database searches by searching the annual meetings of appropriate organisations (e.g. British Association
of Dermatologists Annual Meeting, American Academy of Dermatology Annual Meeting, European Academy of Dermatology and
Venereology Meeting, Society for Melanoma Research Congress, World Congress of Dermatology, European Association of Dermato
Oncology); however, due to volume of evidence retrieved from database searches and time restrictions we were unable to do this.
For quality assessment, the QUADAS-2 tool was further tailored according to the review topic and to cover both melanoma and
keratinocyte skin cancers. In terms of analysis, we did not restrict analysis of per patient data due to lack of data. Sensitivity analyses
were not performed as planned due to lack of data.
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